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Abstract
N-methyl D-aspartate (NMDA) receptors are calcium permeable, glutamategated ion channels that mediate many forms of synaptic plasticity in the central
nervous system. Due to their pivotal role in regulating synaptic plasticity, a
canonical correlate of the molecular and cellular basis for learning and memory,
they are implicated in the pathophysiology of various neurological disorders.
Recently, advances in genome sequencing has identified the NMDA receptor to
be intolerant to genetic variation, as variation often leads to disease. For
example, mutations in the GluN2A subunit of the NMDA receptor are implicated
in the etiology of severe epilepsy-aphasia spectrum disorders. Here we selected
six gain-of-function mutations identified in patients with epilepsy-aphasia
spectrum disorders and characterized their sensitivity to inhibition by GluN2Aselective negative allosteric modulators. We found that GluN2A-selective
negative allosteric modulators can inhibit all the GluN2A gain-of-functioncontaining NMDA receptors tested, despite the location of the mutation in the
receptor. However, we also found no clear evidence that transfection of GluN2A
gain-of-function mutations is toxic or causes overt hyperexcitability in cultured
cortical neurons or CA1 pyramidal neurons of the hippocampus. These data
indicate that while GluN2A-selective negative allosteric modulators can inhibit
NMDA receptors harboring GluN2A gain-of-function mutations, the presence of
mutated GluN2A may not directly cause cell toxicity or hyperexcitability, at least
in cultured neuronal systems.
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Negative allosteric modulation of NMDA
receptors with GluN2A gain-of-function
mutations
1.0 General introduction to chemical neurotransmission
The primary mode of intercellular communication in the central nervous system is
defined as electrochemical neurotransmission. This mode of communication is unique
to the cells of our nervous system and is responsible for translating our experiences into
quantifiable cellular and molecular phenomena. As its name implies, electrochemical
transmission encodes information by use of both chemical flux as well as generation of
electrical potential changes within and around cells.
The general flow of electrochemical neurotransmission proceeds as follows: A
chemical message released from the axon terminal of a pre-synaptic neuron reaches
the receiving, post-synaptic neuron to activate transmembrane proteins. These postsynaptic proteins translate the neurotransmitter signature into an electrical current which
can spread throughout the receiving neuron. Once the propagating current reaches the
axon terminal, the message is converted back into a chemical code to continue the
spread of information.
While neurotransmission is controlled by various neurotransmitter types, the two
primary drivers are glutamate and gamma-aminobutyric acid (GABA), which together
largely drive excitatory and inhibitory neurotransmission, respectively. Maintaining the
proper balance of excitatory and inhibitory neurotransmission is pivotal to sustaining a
healthy nervous system, and unsurprisingly, neurological disorders can result when
excitation or inhibition is skewed in any direction. For example, if the nervous system is
too excitable, synchronous, electrical discharges could accumulate and cause
epileptiform activity. Alternatively, inhibitory tone could dominate and result in whole
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organism sedation, as seen with barbiturate administration. Chronic imbalances in
excitatory and inhibitory neurotransmission can essentially rewire the brain and lead to
neuropsychiatric disorders, like schizophrenia. Recent evidence indicates that
schizophrenia is a manifestation of a chronic increase in inhibitory tone (for more detail
the reader is referred to the section on NMDA receptors in disease).
This dissertation primarily focuses on a subset of mutations that perturb the
excitatory/inhibitory balance. Consequences of this shift spans disruptions in
neurodevelopment and synaptic plasticity homeostasis, causing detrimental outcomes
including epilepsy (Addis et al., 2017; Chen et al., 2017; Endele et al., 2010; Yuan et al.,
2014; Gao et al., 2017; Ogden et al., 2017; Xu et al., 2018). Herein, we characterize
these mutations in various model systems and assess potential amelioration with
selective pharmacological tools.
1.1 Ionotropic glutamate receptors and synaptic transmission
Ionotropic glutamate receptors (iGluRs) are the primary drivers of glutamatergic
excitatory transmission and inherently play major roles in dictating the stability of the
excitatory/inhibitory balance. The iGluRs are ubiquitously expressed glutamate-gated
cation channels and are subcategorized into three groups: AMPA, kainate, and NMDA
receptors (Review - Traynelis et al., 2010). Both AMPA and kainate receptors modulate
fast monovalent excitatory neurotransmission but have different expression profiles.
While AMPA receptors are universally expressed throughout the CNS, kainate receptor
expression is more discretely localized, with greatest expression in the cortex, striatum,
and hippocampus (Bahn et al., 1994).While NMDA receptors share a similar expression
pattern to AMPA receptors, their requirements for activation diverge from both AMPA
and kainate receptors. In addition to glutamate binding, NMDA receptors require
simultaneous binding of glutamate and a co-agonist, glycine or D-serine, along with
concurrent membrane depolarization to relieve tonic Mg2+-mediated inhibition (Johnson
and Ascher, 1987; Kleckner and Dingledine, 1988; Benveniste and Mayer, 1991;
Clements and Westbrook, 1991, 1994). When all these requirements are fulfilled,
NMDA receptors open and mediate the influx of both mono- and divalent cations,
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including Ca2+ (Figure 1.1) (MacDermott et al., 1986; see Traynelis et al., 2010 for
review).
In addition to depolarizing the surrounding dendrite, NMDA receptor mediated
Ca2+ permeability promotes activation of second messenger signaling cascades
important for transducing experiences into quantifiable differences in synaptic strength
(i.e. synaptic plasticity) (Lisman 1987) Review - Nicoll). Apart from GluA2 subunit
lacking AMPA receptors, both AMPA and kainate receptors are impermeable to Ca2+. In
this respect, AMPA and kainate receptors drive postsynaptic depolarization to act as the
first step in this NMDA receptor orchestrated coincidence detection system, where the
final step results in NMDA receptor mediated Ca2+ influx. Ca2+ levels are tightly
regulated in cells (Review – Clapman, 2007) and when internal concentrations diverge
A

B

Figure 1.1: Ligand binding sites and ion
permeation in iGluRs. A) AMPA and
kainate receptors activate upon binding of
glutamate and are permeable to
monovalent cations. B) NMDA receptors
require binding of glutamate and glycine, or
D-serine, along with concomitant
membrane depolarization to relieve a tonic
Mg2+ block to open the ion channel pore,
which is permeable to both mono- and
divalent cations. Adapted from Principles of
Neuroscience, 5th edition, 2012.

from baseline, various second messenger signaling cascades are activated to influence
long-term potentiation (LTP) or depression (LTD) of synaptic strength (Review - Nicoll,
2017).
LTP and LTD describe the mode of synaptic plasticity and are largely mediated
by NMDA receptor activity. Upon NMDA receptor mediated Ca2+ influx, downstream
targets are activated, and synaptic refinement commences. Acute fluxes of highly
concentrated Ca2+ waves generally lead to LTP, whereas slow, more diffuse Ca2+ influx
dictates LTD (Luscher and Malenka, 2012; Review - Nicoll, 2017). As such, LTP results
from repetitive, high frequency stimulation that often leads to AMPA receptor
recruitment to the synapse (Hayashi et al., 2000; Lushcer and Malenka 2012; Jurado et
3

al., 2013). Greater prevalence of synaptic AMPA receptors renders the postsynaptic
dendrite more sensitive to presynaptic neurotransmitter release, and consequently more
likely to depolarize. With a greater likelihood of depolarization, NMDA receptors are
essentially primed for activation of further Ca2+ influx. This feed-forward cycle results in
more AMPA receptor recruitment and an increase in synaptic surface area, as
evidenced by the formation of mushroom spines.
LTD results from low frequency stimulation, leading to a slow and dispersed Ca2+
accumulation. This more nebulous Ca2+ flux activates protein phosphatases, instead of
kinases as with LTP, and leads to downstream signaling that promotes synaptic
destabilization. Mechanisms of LTP and LTD are widely regarded as the cellular and
molecular substrates for learning and memory formation, along with memory extinction,
and are highly dependent on NMDA receptor activity (Review – Nicoll, 2017).
1.2 Structure and functional properties of NMDA receptors
1.2.1 NMDA receptor structure
NMDA receptors assemble as a dimer of dimers consisting of two GluN1
subunits complexing with either two GluN2 or GluN3 subunits (Lee and Gouaux, 2011;
Monyer et al., 1992; Schorge and Colquhoun, 2005; Traynelis et al., 2010; Ulbrich and
Isacoff, 2007, 2008). Finetuning of NMDA receptor responses is dictated by subunit
composition, and this inherent functional diversity is enhanced by the various splice and
gene variants within the individual subunits themselves. The GluN1 subunit, encoded by
the GRIN1 gene, exists in eight different splice variants, four different GluN2 subunits
have been identified (GluN2A-D) encoded by distinct genes (GRIN2A-D), and two
different GluN3 subunits exist (GluN3A-B) encoded by two genes (GRIN3A-B). GluN1
and GluN3 subunits bind the co-agonists glycine or D-serine, whereas GluN2 subunits
bind glutamate.
NMDA receptor subunits assemble in an alternating pattern (GluN1-GluN2GluN1-GluN2), with alike subunits arranged across from one another with two-fold
symmetry (Figure 1.2) (Karakas and Furukawa, 2014, Riou et al., 2012). Each subunit
has an extracellular amino-terminal domain (ATD), agonist binding domain (ABD),
transmembrane domain (TMD), and carboxy-terminal domain (CTD). The ATD is
4

involved in NMDA receptor subunit assembly and the target of both endogenous and
exogenous allosteric modulators (Khatri et al., 2014; Kaiser et al., 2018). The ABD is
sculpted from two discontinuous segments of the polypeptide chain (S1 and S2) to
resemble a clamshell that bites down upon agonist binding. The transmembrane
domain consists of three transmembrane helices (M1, M3, and M4), which transduce
agonist binding to channel opening, and a membrane-reentrant loop (M2) that forms a
narrow constriction in the central ion channel pore and thereby renders the channel
sensitive to Mg2+ block and regulates channel permeability (Schneggenburger and
Ascher, 1997; Ren et al., 2003; Talukder et al., 2010; Kazi et al., 2013). The CTD
extends into the cytoplasm and provides a scaffold for receptor trafficking and signal
transduction (Aman et al., 2014; Lussier et al., 2015). As depicted in Figure 1.2,
subunits arrange as a “dimer of dimers”, with the ATD more loosely packed and
unfurling into the extracellular environment (Traynelis et al., 2010).
Crystallographic structures of NMDA receptors reveal striking similarly to AMPA
and kainate receptors. Notably, all iGluR members arrange in a layered symmetry
among the TMD, ABD, and ATD. The TMD adopts a quasi-four-fold symmetry and the
extracellular ABD and ATDs assemble with a two-fold, dimer-of-dimers axis of
symmetry (Figure 1.2) (Sobolevsky et al., 2010). Salient differences among NMDA and
AMPA/kainate receptors are localized to the ABD and ATD domains. Comparably,
NMDA receptors have more points of contact along the ABD interface, which creates a
structurally established line of allosteric interaction among the ABD heterodimers
A

B

Figure 1.2: NMDA receptor domain
symmetry. A) Structure of a GluN1/GluN2B
NMDA receptor with domains indicated. The
CTD is excluded. B) GluN1 and GluN2
subunits arrange in a 1-2-1-2 alternating
pattern in the ATD and ABD and show quasifour-fold symmetry in the TMD. Note that the
1-2-1-2 arrangement interchanges between
subdomains (i.e. subunit arrangement is
mirrored between ATD and ABD domains).
Adapted with modifications from Hansen et
al., 2018.
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(Karakas and Furukawa, 2014; Lee et al., 2014). These contacts may help explain
glycine potency disparities among GluN2 subunits. Similarly, NMDA receptors have
more points of interaction between the ATD-ABD interface as compared to
AMPA/kainate receptors (Reagan et al., 2018). This results in a more compact ATD,
resembling a hot air balloon compared to the diffuse Y-shaped ATD seen in
AMPA/kainate receptors. This could be the reason that the ATD in NMDA receptors, but
not AMPA receptors, harbors binding sites for allosteric modulators and is itself an
allosteric domain that controls many biophysical properties that are different between
the NMDA receptor subtypes.
1.2.2 NMDA receptor function
Glutamate is released from presynaptic vesicles and persists in the synapse at a
concentration of approximately 1.1mM ,which decays with a time constant of 1.2 ms
(Clements et al., 1992). Upon presynaptic release of glutamate, AMPA/kainate
receptors deactivate rapidly (τdeact 1-2ms), while NMDA receptors deactivate orders of
magnitude slower (τdeact 50-500ms). This incongruity in kinetics further reinstates the
coincidence detector nature of NMDA receptors. Due to their slow time course of
activation and deactivation, they can integrate frequency patterns of presynaptic
neurotransmitter release into salient signals of synaptic strength.
NMDA receptor kinetics are controlled by agonist affinity, pre-gating steps, and
transitions between gating states. Though desensitization plays a prominent role in
regulating kinetic properties in AMPA/kainate receptors, desensitized NMDA receptors
only represent a small fraction of activated receptors (Zhang et al., 2008). Instead,
NMDA receptor kinetics are described by a series of pre-gating steps followed by
transitions between both glutamate-bound closed and open states, until glutamate
eventually unbinds. Upon brief exposure to glutamate, NMDA receptors proceed
through agonist binding, pre-gating, gating, with individual transitions between these
states, ultimately resulting in agonist unbinding over the time course of hundreds of
milliseconds, which conveniently mirrors the overall decay time course of excitatory
postsynaptic currents (Lester et al., 1990; Hestrin et al., 1990; Bourne and Nicoll, 1993;
Seeburg et al., 1995).
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NMDA receptor heterogeneity is illustrated through the distinct temporal and
spatial properties of GluN2 subunits. Pharmacological properties vary in deactivation
kinetics, channel conductance, channel open probability, agonist potencies, Ca 2+
permeability, sensitivity to Mg2+ block, and sensitivity to endogenous inhibitors (i.e. Zn2+
and H+) (Monyer et al., 1992; Vicini et al., 1998; Wyllie et al., 1998; Erreger et al., 2004;
Erreger et al., 2007; Chen et al., 2008; Hansen et al., 2008; Yuan et al., 2009; Glasgow
et al., 2015 for review). GluN2A and GluN2B containing NMDA receptors have high
Ca2+ permeability, channel conductance, and sensitivity to Mg2+ block. Conversely,
GluN2C and GluN2D containing NMDA receptors have lower Ca2+ permeability,
channel conductance, and sensitivity to Mg2+. Furthermore, GluN2A containing NMDA
receptors show the fastest deactivation kinetics, lowest agonist potencies, and greatest
open probability, whereas GluN2B, GluN2C and GluN2D- containing NMDA receptors
have much slower deactivation kinetics, greater affinity for agonists, and lower open
probabilities. Binding and regulation by endogenous inhibitors are highly variable among
subtypes, with no clear trend. GluN2A, GluN2B, and GluN2D containing NMDA
receptors are sensitive to proton-mediated inhibition, whereas only GluN2A containing
NMDA receptors are sensitive to Zn2+-mediated inhibition (For review see Paoletti et al.,
2013 and Glasgow et al., 2015).
NMDA receptors are activated by the agonist glutamate and co-agonists glycine
and D-serine. Glutamate is released pre-synaptically and is cleared from the synaptic
space by excitatory amino acid transporters (EAATs) on a millisecond timescale
(Danbolt 2001). Inversely, co-agonists are ambiently present and suggested to remain
unsaturated at synaptic NMDA receptors receptors (Bergeron et al., 1998; Billups and Li
et al., 2009). Since simultaneous agonist binding to all four subunits in the NMDA
receptor is required for activation, phasic glutamate activation of NMDA receptors is
akin to switching a speaker on/off, whereas tonic glycine or D-serine is analogous to the
volume button.
Due to glutamate’s role in turning NMDA receptors on/off, its concentration is
tightly controlled. Recent efforts have targeted co-agonist modulation in hopes to finetune NMDA receptor responses. Glycine regulation has proven difficult due to various
off-target effects and unsuccessful clinical outcomes (Cioffi 2018). This may be
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attributed to glycine’s involvement in both sides of the excitatory and inhibitory balance.
Glycine drives inhibitory tone through activation of inhibitory glycine receptors, while
simultaneously increasing excitatory drive via its role as a co-agonist for excitatory
NMDA receptors. Additionally, glycine modulates NMDA auto-receptor activation,
internalization of NMDA receptors, and serine racemase activity (Zhang et al., 2008;
Musante et al., 2011; Nong et al., 2003; Dunlop and Neidle, 2005; Marchetti et al.,
2013). As such, D-serine modulation has become a popular research focus.
D-serine is synthesized from L-serine by serine racemase (SR) (Wolosker et al.
1999a), and ambient levels are regulated by two families of neutral amino acid
transporters: the sodium-independent alanine-serine-cysteine transporters (asc-1) and
the sodium-dependent alanine-serine-cysteine transporters (ASCT1 and ASCT2)
(Fukasawa et al., 2000; Nakauchi et al., 2000). The current model suggests that asc-1
mediates efflux of D-serine from neurons, while the ASCTs facilitate influx of D-serine
into astrocytes (Rosenberg et al., 2013; Wolosker et al., 2016; Foster et al., 2016).
These properties are supported by studies employing use of small molecule inhibitors,
where inhibiting asc-1 impairs LTP (Sason et al., 2017). Recently, Papouin and
colleagues (2012) postulated D-serine as the principal synaptic co-agonist, and
inversely, glycine as the preferential co-agonist at extra-synaptic NMDA receptors. This
relationship favors targeting D-serine levels to treat neurological disorders involving
synaptic NMDA receptor dysregulation.
1.3 NMDA receptor subunit expression
1.3.1 GluN1 splice variants
GluN1 expression begins as early as embryonic day 14 and sustains extensive
expression throughout life (Monyer et al., 1992). GluN1 is encoded by a single gene,
GRIN1, with eight distinct isoforms (GluN1-1a to GluN14a and GluN1-1b to GluN1-4b),
resulting from alternative splicing of three different exons (exon 5, 21, and 22)
(Dingledine et al., 1999). Exon 5 is in the ATD and is present in GluN1-a and absent in
GluN1-b isoforms, while the remaining alternatively spliced exons (21 and 22) are
located in the CTD. GluN1 isoforms contain both CTD exons, GluN1-2 lacks exon 21,
GluN1-3 lacks exon 22, and GluN1-4 lacks both CTD exons (Figure 1.3).
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Figure 1. 3 Expression and functional properties of GluN1 splice variants. A)
Autoradiogram showing the temporal and spatial expression of GluN1 splice
variants. Ac nucleus accumbens, Cb cerebellum, Cp caudate-putamen, Cx cortex,
DG dentate gyrus, DP dorsal pons, Hi hippocampus, Ob olfactory bulb, Th thalamus,
VPn ventro-posterial thalamic nuclei. Modified from Paupard et al. 1997. B)
Polypeptide linear representation of the 8 GluN1 splice variants. Exon 5 is in the
ATD and is present in GluN1-a and absent in GluN1-b isoforms, while the remaining
alternatively spliced exons (21 and 22) are located in the CTD. GluN1 isoforms
contain both CTD exons, GluN1-2 lacks exon 21, GluN1-3 lacks exon 22, and
GluN1-4 lacks both CTD exons. Adapted from Hansen et al., 2018. C) Ifenprodil
concentration-inhibition data acquired in Xenopus oocytes expressing relevant
subunits. NMDA receptors containing GluN1-1b subunits (i.e. containing exon 5)
show reduced potencies to infenprodil. Adapted from Hansen et al., 2018.
NMDA receptors containing GluN1-b isoforms have decreased agonist potencies
and shorter durations of channel opening (Traynelis et al., 1995; Rumbaugh et al.,
2000; Vance et al., 2012; Yi et al., 2018). Similarly, ifenprodil, zinc, and proton
sensitivity are also reduced in GluN1-b/GluN2B containing NMDA receptors (Figure
1.3C). These pharmacological differences are postulated to arise from interactions
between ATD and ABD domain contacts among GluN1 and GluN2 subunits (Reagan et
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al., 2018). Alternative splicing in the CTD (exons 21 and 22) influences NMDA receptor
trafficking (Scott et al., 2003) and binding to intracellular proteins, including calmodulin
(Ehlers et al., 1996 ; Wenthold et al., 2003 for review).
Once established shortly after birth, GluN1 isoform expression remains stable
throughout life. GluN1-a isoforms are expressed universally in the CNS, while GluN1-b
isoforms are restricted to the sensorimotor cortex and thalamus. Similarly, GluN1-2
isoforms are widely expressed, whereas GluN1-1 and GluN1-4 expression is regionally
restricted. GluN1-1 is prevalent in rostral areas (cortex, hippocampus, caudate) while
GluN1-4 is localized to caudal regions (thalamus, cerebellum, colliculi). GluN1-3
expression is the lowest, with levels hardly detected in the cortex and hippocampus
(Ewald and Cline, 2009 for review).
1.3.2 GluN2 subunits
GluN2 subunit expression largely dictates NMDA receptor functional
heterogeneity. Temporal and spatial expression of GluN2 subunits is tightly regulated
and gives rise to the fine-tuning of NMDA receptor responses throughout the brain. As
seen in Figure 1.4, GuN2B and GluN2D are temporally intertwined as they are both
expressed embryonically and dissipate into adulthood. Contrary, GluN2A and GluN2C
aren’t present in the embryo, but rather become more prevalent as the organism
matures (Monyer et al., 1994).
A

B
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Figure 1.4: Expression and functional properties of GluN2A subunits. A)
Autroradiogram showing the temporal and spatial expression patterns of GluN2
subunits. Modified from Akazawa et al., 1994). B) Whole cell patch-clamp recordings
of responses from synaptic-like application of 1mM glutamtate in diheteromeric
NMDA receptors. The open tip current defines the extent of glutamate exposure,
which was approximately 1ms. Adapted from Vicini et al., 1998)
In the mature brain, subunit expression is similarly parsed out for distinct
functional profiling. GluN2A is primarily expressed in the neocortex and cerebellum,
GluN2B is confined to the forebrain, GluN2C is found primarily in the cerebellum, and
GluN2D is restricted to the diencephalon and mesencephalon. Within the hippocampus,
subunit specificity extends into neuronal cell types. GluN2A and GluN2B subunits are
found in CA1 and CA3 pyramidal cells, whereas GluN2C and GluN2D are restricted to
different subsets of interneurons (Monyer et al., 1994).
The properties discussed thus far regard diheteromeric NMDA receptors that contain
GluN1 and one type of GluN2 subunit (e.g. GluN1/2A), though most neurons express at
least two different GluN2 subunits. In fact, within the hippocampus and cortex, it has
been estimated that the majority of NMDA receptors in pyramidal cells are
triheteromeric GluN1/GluN2A/GluN2B receptors (Al-Hallaq et al., 2007; Luo
et al., 1997; Rauner and Kohr, 2011; Sheng et al., 1994; Tovar et al., 2013; Review Chazot and Stephenson, 1997). Our understanding of the structural and functional
properties of triheteromers is limited due to difficulties in reliably expressing
triheteromers, but a recent advance in triheteromer cell surface expression has
expanded the scope of research abilities and lends promise to the further elucidation of
these complex assemblies (Hansen et al., 2014). Due to this novel method, other
triheteromeric complexes have been studied in more detail, including
GluN1/GluN2A/GluN2C and GluN1/GluN2B/GluN2D. While NMDA receptors containing
GluN1/GluN2A/GluN2C and GluN1/GluN2B/GluN2D exhibit intermediate properties
seen in diheteromers (Hansen manuscript in preparation), GluN1/GluN2A/GluN2B
triheteromeric assemblies are instead dominated by GluN2A associated properties (Sun
et al., 2017). Therefore, GluN1/GluN2A and GluN1/GluN2A/GluN2B exhibit similar
properties in terms of open probability and deactivation kinetics. This property bolsters
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the reliance of the developmental switch to GluN2A dominated synaptic NMDA
receptors.

1.4 NMDA receptors in brain function and disease
NMDA receptors facilitate neuronal communication by correlating time-dependent
activity between neurons. Communication among neurons is necessary for survival and
successful signal integration can result in new connections, maintenance of current
contacts, and weakening of others. Due its pivotal role in shaping synaptic contacts,
NMDA receptors regulate development and maintenance of the nervous system.
In neurodevelopment, NMDA receptor subunit expression is modulated to
coordinate synapse formation and maturation. As synapses converge and establish
communications, postsynaptic GluN2B-containing NMDA receptors act to promote
synaptic stability and neuron survival. As neocortical development proceeds, GluN2A
subunit expression commences and triggers synaptic refinement (Monyer et al., 1994;
Sheng et al., 1994), a necessary process of maturation. Aberrant subunit expression or
regulation has deleterious effects on proper neurodevelopment and maintenance,
primarily regarding deficits in network formation and refinement. These deficits are
postulated drive the pathophysiology of neurological disorders ranging from intellectual
disability to epilepsy.
Similarly, NMDA receptor modulation dictates synaptic plasticity throughout life.
Alterations in NMDA receptor signaling can have adverse outcomes no matter the stage
in life, whether it contributes to neurodevelopmental disorders or propagation of agerelated dementias. Age-related dementias like Alzheimer’s disease don’t necessarily
involve mutated or malfunctioning NMDA receptors, but rather lose proper regulation of
NMDA receptor activity. This can result from hyper- or hypoactivation of NMDA
receptors, which may be caused by dysregulation of agonist/co-agonist levels
(Peyrovian et al., 2019).
Aberrant NMDA receptor signaling can result in the uncoupling of associated
plasticity, unregulated feedback loops, and ultimately cell death. For example, chronic
activation of extrasynaptic NMDA receptors leads to a diffuse Ca 2+ influx and activation
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of signaling cascades that favor cell death and LTD (Zhang et al., 2007; Leveille et al.,
2008; Ivanov et al., 2006). The idea that synaptic activation of NMDA receptors
promotes cell survival and synaptic strengthening, whereas extrasynaptic activation
promotes cell death and synaptic weakening is explored through the lens of various
neurological disorders below.
1.4.1 Ischemia
During episodes of ischemia, glutamate transport is reversed, and instead of
clearing excess glutamate, the glial EAAT2 transporter redirects transport and begins to
release glutamate (Danbolt 2001). Excessive glutamate concentrations extensively
activate NMDA receptors, and other iGluRs, which results in acute excitotoxicity. The
NMDA receptor’s role in ischemia induced excitotoxicity is delineated by the fact that
NMDA receptor antagonists are neuroprotective both in vitro and in vivo following an
ischemic insult (Simon et al.,1984; Chen et al.,1991, 2008; Liu et al., 2007).
Furthermore, NMDA receptor subunits contribute differently to the propagation of
excitotoxicity, with GluN2B-selective antagonists alleviating excitotoxicity, while GluN2A
antagonists exacerbate excitotoxicity-mediated neuronal cell death (Liu et al., 2007;
Chen et al., 2008). A GluN2B-selective antagonist has shown clinical efficacy in
reducing infarct volume if given two hours after stroke onset (Yang et al., 2003),
whereas non-selective NMDA receptor antagonists need to be administered before
stroke onset to protect against ischemic cell death (Liu et al., 2007; Margaill et al., 1996;
Chen et al., 2008). Furthermore, decoupling of GluN2B scaffolding proteins, including
PSD-95 and death-associated protein kinase-1, has been shown to protect neurons
against ischemic insults (Aarts et al., 2002; Tu et al., 2010).
1.4.2 Alzheimer’s disease
In Alzheimer’s disease, amyloid-β peptides have been found to increase
intracellular Ca2+ accumulation via activation of extrasynaptic-containing GluN2B
receptors (Ferreira et al., 2012). Ablation of GluN1 and GluN2B extracellular terminals,
but not of GluN2A, in cortical cultures prevented binding of amyloid-β oligomers to
NMDA receptors (Costa et al., 2012). Furthermore, extrasynaptic activation of NMDA
receptors led to an increase in amyloid-β secretion in cortical cultures (Bordji et al.,
2010). GluN2B antagonists were also able to rescue impairments in LTP (Rönicke et al.,
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2011; Li et al., 2011), amyloid-β facilitation of LTD (Li et al., 2009), and synaptic loss
(Rönicke et al., 2011; Liu et al., 2010). Similar to ischemic insults, a decoupling of
GluN2B with PSD-95 was able to prevent amyloid-B induced toxicity, including memory
deficits and improved survival in a mouse model of Alzheimer’s disease (Ittner et al.,
2010).
1.4.3 Depression
The etiology of depression is highly heterogeneous and can result from a
multitude of both genetic and environmental factors including monoamine deficiencies,
impaired circadian rhythms, aberrant hypothalamic-pituitary-axis activity, reduced
GABA-ergic activity, and NMDA receptor dysfunction (Review - Hasler 2010). Despite
this diverse pathological profile, the monoamine hypothesis of depression has
dominated clinical treatment strategies (Mann 2005). However, serotonin-reuptakeinhibitors and similar monoamine targeting treatments have a delayed onset of action
and limited efficacy in treating depression. This lends to the hypothesis that the
monoamine system is a downstream consequence of a separate upstream abnormality.
The glutamate hypothesis of depression is supported by use of NMDA receptor
antagonists and glutamate release inhibitors (Kendell et al., 2005). Administration of
ketamine to patients with treatment-resistant major depressive-disorder produced rapid
and substantial antidepressant effects (Zarate et al., 2006). Ketamine is thought to
counteract depression via inhibition of NMDA receptor-mediated spontaneous activity of
GABAergic inhibitory interneurons, fortifying the hypothesis that depression results from
an increase in inhibitory drive (Homayoun and Moghaddam, 2007). A GluN2B
antagonist, Ro 25-6981, showed similar results to ketamine in both mechanism of
action, onset, and longevity (Li et al., 2011). Due to the success seen with NMDA
receptor antagonists, the FDA has recently approved a ketamine-laced nasal spray for
treatment-resistant depression (2019).
1.4.4 Epilepsy
Epilepsy is a result of hypersynchronous electrical discharges that result in
overactivation of the excitatory system. Ketamine has shown success in neuroprotection
and reducing neuroinflammation when administered during status epilepticus (i.e. a
seizure lasting more than five minutes) (Dorandeu et al., 2013). Similarly, MK-801 (an
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NMDA receptor antagonist) administration after 90 minutes of status epilepticus was
shown to be neuroprotective, but like ketamine, failed to prevent future seizures (Brandt
et al., 2003). A GluN2B antagonist, ifenprodil, has also shown to mirror the
neuroprotective action of broad-spectrum NMDA antagonists, like MK-801, in epilepsy
models. Additionally, GluN2B extrasyanptic expression increases, while synaptic
expression decreases following an epileptic event (Frasca et al., 2011). This suggests
that epileptogenesis is not solely mediated by NMDA receptors, albeit NMDA receptor
hyperactivation is a contributor to neuronal cell death during seizures. However, there
has been some success with memantine mediated epileptiform reduction in a patient
with a GluN2A gain-of-function mutation, although memantine was unable to rescue the
associated cognitive deficits (Pierson et al., 2014).
1.4.5 Schizophrenia
Similar to depression, schizophrenia has traditionally been considered a
monoamine disorder. While targeting the dopaminergic system alleviates the positive
symptoms (i.e. hallucinations) associated with schizophrenia, hyperactive dopaminergic
signaling does not explain the negative or cognitive deficits. (Moghaddam and Javitt,
2012; Lewis, 2012). Again, as with depression, this suggests that monoamines play a
downstream role and once again the glutamate hypothesis is implicated in disease
etiology. However, unlike depression, schizophrenia is thought to result from
hypofunctioning NMDA receptors located in interneurons (Moghaddam and Javitt,
2012).

Evidence fortifying the NMDA receptor hypofunction hypothesis includes: 1)
NMDA receptor antagonists can reproduce schizophrenia-like symptoms in healthy
humans (Coyle, 2006). 2) Reduced NMDA receptor expression (specifically GluN2A
subunits) is seen in parvalbumin interneurons in post-mortem samples from individuals
with schizophrenia (Belforte et al., 2010). 3) Depletion of D-serine, a selective coagonist at NMDA receptors, can cause schizophrenia-like behaviors in mice (Labrie et
al., 2009), and reduced levels of D-serine have been reported in the cerebrospinal fluid
and blood of schizophrenic patients (Hashimoto et al., 2003). 4) D-serine administration
can rescue schizophrenia induction by PCP, an NMDA receptor antagonist similar to
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ketamine (Anderson et al., 2004). These data implicate that enhancing NMDA receptor
activity could ameliorate deficits in inhibitory drive seen in patients with schizophrenia.
1.5 De novo GRIN mutations
De novo mutations are spontaneously occurring, i.e. they are not inherited across
generations. There are fewer single nucleotide polymorphisms, aka de novo mutations,
in GRIN genes than to be expected, indicating that GRIN genes are highly intolerant to
variation (Petrovski et al., 2013). Recently, XiangWei and colleagues (2018) assessed
258 GRIN variants which are not present in the healthy human population (gnomAD
database assessed August 2, 2017). Of these 258 single nucleotide polymorphisms,
10% resided in GluN1, 39% in GluN2A, 45% in GluN2B, 3% in GluN2C, and 3% in
GluN2D. Additionally, 65% of these mutations were found to be missense, 9%
nonsense, 9% frameshift, 5% splice site, and 12% were uncategorized.
Mutations in single subunits are often comorbid with neuropsychiatric disorders.
For example, 77% of patients with an NMDA receptor mutation present with intellectual
disability, 49% with epilepsy, 19% with autism spectrum disorder, 5% with
schizophrenia, and 2% with attention deficit hyperactivity disorder. The most prevalent
behavioral outcome associated with mutations in GluN1, GluN2B or GluN2C was
intellectual disability, while epilepsy was highly correlated with mutations in GluN2A,
and GluN2D mutations were associated with schizophrenia.
As GluN1 is expressed universally in both temporal and spatial respects, It is
unsurprising that mutations are more likely to result in intellectual disability with or
without comorbid epileptiform activity. On the molecular and cellular level, intellectual
disability can manifest as the inaccurate encoding of information between and among
neurons. Similarly, GluN2B shares a similar phenotypic outcome in regard to
prevalence of intellectual disability due to its prevalence in synapse formation and
stabilization during development. GluN2A on the other hand is highly associated with
epilepsy, with 78% of patients presenting with symptoms falling under the epilepsyaphasia spectrum disorder phenotype (XiangWei et al., 2018).
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1.5.1 Epilepsy-aphasia spectrum disorders
The epilepsy-aphasia spectrum (EAS) is a broadly defined category of abnormal
CNS electrical activity coupled with language loss and in severe cases, intellectual
disability. Language impairments can include deficits in reading, writing, and speaking
and appear in early childhood. In severe cases, children develop EAS months after
birth, while children with more moderate EAS begin showing symptoms around five
years of age.
Epileptiform profiles of EAS include Landau-Kleffner syndrome, epileptic
encephalopathy with continuous spike-and-wave during sleep syndrome, and various
forms of benign childhood epilepsy with centrotemporal spikes. Both Landau-Kleffner
syndrome and epileptic encephalopathy with continuous spike-and-wave during sleep
syndrome show abnormal epileptiform activity (i.e. spike-and-wave discharges) during
more than 85% of slow-wave sleep, whereas abnormal EEG activity seen in benign
childhood epilepsy with centrotemporal spikes occurs in less than 85% of slow-wave
sleep. These three main classifications of epileptiform activity seen in EAS all share the
same attribute of manifesting during sleep and largely remitting upon awakening.
Benign childhood epilepsy with centrotemporal spikes is the most prevalent childhood
epilepsy and generally presents with mild language loss (Bradley et al., 1990). Seizures
occur in the rolandic area of the brain and generally subside at the end of adolescence,
hence its benign classification. Conversely, Landau-Kleffner syndrome and epileptic
encephalopathy with continuous spike-and-wave during sleep syndrome are more
severe forms of EAS, and in some cases, present earlier and do not subside upon
adulthood. Individuals with epileptic encephalopathy with continuous spike-and-wave
during sleep syndrome show nearly continuous (≥85%) high amplitude bilateral slow
spike wave activity during non-rapid eye movement sleep. Children with LandauKleffner syndrome show similar EEG patterns, but don’t develop language loss until
around five years of age (Carvill et al., 2013).
The etiology of EAS is still being uncovered, though recently whole exome
genome sequencing lead by the National Institute of Health (NIH) Undiagnosed
Diseases Program (UDP) elucidated the role of GRIN2A mutations in EAS. Mutations in
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GluN2A subunits are more prevalent in severe forms of EAS, accounting for up to 20%
of children with Landau-Kleffner syndrome and epileptic encephalopathy with
continuous spike-and-wave during sleep syndrome, while only being implicated in about
5% of children with benign childhood epilepsy with centrotemporal spikes. The current
treatment strategies include general anticonvulsants and corticosteroids, albeit these do
not ameliorate cognitive deficits associated with EAS.
1.6 Possible strategies for NMDA receptor modulation in disease
Dysfunctional NMDA receptors underlie various forms of neurological disorders
and accordingly, serve as an attractive therapeutic target for clinical intervention. While
many NMDA receptor modulators have been approved for clinical trials, few have
shown significant improvement of NMDA receptor-mediated neurological disorders. One
pharmaceutical, memantine, has shown clinical success in treating moderate-to-severe
Alzheimer’s disease and has been approved by the Food and Drug Administration
(FDA). Memantine is a non-selective open channel blocker, which is just one flavor of
modulation possible for NMDA receptors. NMDA receptors can also be modulated by
more indirect means, including NMDA receptor trafficking.
1.6.1 Modulating NMDA receptor trafficking
Synaptic activity and efficacy can be regulated by NMDA receptor trafficking to
and within the plasma membrane (Barria et al., 2002). Within hours after synaptic
activity, NMDA receptor trafficking is initiated to and from synapses (Quinlan et al.,
1999), and synaptic retention and release is dependent on future synaptic activity (Rao
et al., 1997). NMDA receptor trafficking is targeted via the CTD and different subunits
have altered proclivities to endo- and exocytosis (for review see Perez-Otano and
Ehlers 2005). For example, alternative splicing of the GluN1 CTD to include the C2
cassette (GluNR1-3a and 3b) facilitates trafficking to the membrane (Scott et al., 2001;
Okabe et al., 1999). Additionally, phosphorylation by protein kinase C promotes dual
properties of NMDA receptor regulation by both promoting translocation from synaptic to
extrasynaptic sites (Fong et al., 2002) and exocytosis of NMDA receptors from the
endoplasmic reticulum (Scott et al., 2003; Lan et al., 2001). Finally, GluN2A and
GluN2B differ in their affinity for internalization, where GluN2B is more readily
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internalized due to amino acid motifs in the CTD which attract internalization machinery
more effectively than GluN2A subunits (Lavezzari et al., 2004).
Inhibition of protein kinase C mediated exocytosis can be inhibited by a dominant
negative mutant of soluble NSF-associated protein and botulinum neurotoxin A (Lan et
al., 2001). Similarly, blocking GluN2B associations with PSD-95 to promote lateral
mobility to extrasynaptic sites has been experimentally utilized in Alzheimer’s disease
(Ittner et al., 2010) and neuroprotection in stroke (Aarts et al., 2002). Therefore,
targeting NMDA receptor trafficking could prove to be a valuable therapeutic strategy to
modulate NMDA receptor activity.
1.6.2 Modulation of co-agonist occupancy
Functional evidence has indicated that D-serine is the principal coagonist at
mature excitatory synapses in the hippocampus (Mothet et al., 2000; Yang et al., 2003;
Henneberger et al., 2010; Papouin et al., 2012), hypothalamus (Panatier et al., 2006),
spinal cord (Wake et al., 2001), brainstem (Berger et al., 1998), retina (Stevens et al.,
2010) and prefrontal cortex (Fossat et al., 2012). The degree of saturation in these
regions vary and this poses the possibility that regulation of glycine/D-serine levels may
prove to be an effective therapeutic target for NMDAR hypo- and hyperfunction
disorders. However, since manipulation of glycine has off target effects, like activation of
glycine receptors (Zhang et al., 2007), interaction with NMDA autoreceptors (Musante et
al., 2011), internalization of NMDAR (Nong et al., 2003) and modulation of serine
racemase (Dunlop and Neidle, 2005; Marchetti et al., 2013), controlling D-serine levels
has become a popular research focus.
D-serine was shown to be significantly present in the brain by Hashimoto and
colleagues in 1992. This was a monumental discovery because, canonically, D-amino
acids were not thought to be present in significant concentrations in eukaryotes. After
this revolutionary discovery, the functional importance of D-serine in regulating
physiological processes like neural migration and proliferation (Kim et al., 2005; Huang
et al., 2012), synaptic plasticity (Mothet et al., 2000; Yang et al., 2003; Panatier et al.,
2006; Henneberger et al., 2010; Papuan et al., 2012; Li et al., 2013; Rosenberg et al.,
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2013), and neurotoxicity (Mustafa et al., 2010; Watanabe et al., 2016) has started to
emerge.
D-serine is synthesized by the pyridoxal-5’-phosphate-dependent serine
racemase (SR) (Wolosker et al. 1999a, b,), degraded by the peroxysomal flavoprotein
D-amino acid oxidase (DAAO) (Krebs 1935; Mothet et al., 2000; review see Pollegioni
and Sacchi 2010), and transported across membranes by astrocytic vesicular release
(Mothet et al., 2005; Henneberger et al., 2010) and two known families of neutral amino
acid antiporters. The Alanine-Serine-Cysteine Transporter (ASCT; SLC1A5 and
SLC1A5) belongs to the Solute Carrier family (SLC) of membrane transporters, and in
accordance with the glutamate transporters, is sodium-dependent with a
thermodynamically uncoupled chloride conductance (Zerangue and Kavanaugh, 1996).
Alternatively, the alanine-serine-cysteine transporter-1 (asc-1; SLC7A10) binds with a
single membrane spanning type II membrane glycoprotein (4F2), and is sodiumindependent with no associated conductance (Fukasawa et al., 2000).
Early studies indicated that ASCTs transport D-serine with low affinity, and thus
asc-1 has been the primary research focus for D-serine transport. Asc-1 is localized to
neurons (Helboe et al., 2003) and has a high affinity for D-serine and glycine (Fukasawa
et al., 2000; Nakauchi et al., 2000; Matsuo et al., 2000; Rosenberg et al., 2013).
However, the neuronal supply of D-serine by asc-1 can’t account for all of the D-serine
that is released and available for NMDAR binding (Yang et al., 2003; Rutter et al.,
2007). We have recently shown that ASCTs also transport D-serine, with micromolar
potency (Foster et al., 2016). The current model, termed the D-serine shuttle
hypothesis, supports that asc-1 is responsible for the efflux and ASCT1/2 for the influx
of ambient D-serine (Wolosker et al., 2016). This indicates that therapeutic targets for
these neutral amino acid transporters could ameliorate hyper- or hypoactive NMDA
receptor disorders.
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1.6.3 NMDA receptor ligands
1.6.3.1 – Orthosteric antagonists
Orthosteric antagonists bind in the agonist binding pocket and have been
instrumental in elucidating NMDA receptor’s role in physiological processes. In 1983, a
seminal paper by Collingridge and colleagues showed that an NMDA receptor
antagonist, 2-amino-5-phosphonopentanoate (AP5), was able to prevent induction of
LTP at high frequency stimulation, with minimal modification at low frequency
stimulations (Collingridge et al., 1983). This paper introduced the importance of NMDA
receptors in LTP induction, a finding that had little support before use of AP5 (for review
see Lodge et al., 2018). Additionally, determination of the two-site model (i.e. two
glutamate and two glycine are required for NMDA receptor activity) was elucidated by
use of glutamate and glycine competitive antagonists, AP5 and 7-chlorokynurenic acid
(7CK), respectively (Benveniste and Mayer, 1991).
Despite the utility of competitive antagonists in illuminating the importance and
basic properties of NMDA receptors, discovery of GluN2 subunit-selective antagonists
has been a multi-decade long hurdle for the field. This is attributed to the conservation
of amino acid motifs surrounding the glutamate binding pocket in GluN2 subunits
(GluN2 binds glutamate, GluN1 binds glycine). However, recent progress in selectivity
has surfaced with compounds that extend deeper into the pocket, in the space between
ABDs (Lind et al., 2017).
1.6.3.2 Allosteric antagonists
Allosteric antagonists are defined as ligands that bind anywhere outside the
active site (i.e. orthosteric site) and selective allosteric antagonists exist for all GluN2
subunits. There are various flavors of allosteric antagonism including ion channel
occlusion, desensitization state stabilizers, and negative modulation of agonist binding.
Here we will discuss memantine (a non-selective antagonist), ifenprodil (GluN2B
selective antagonist), and TCN-201 (a GluN2A selective antagonist).
Memantine, a positively charged compound at physiological pH, is considered
an uncompetitive open channel blocker at all NMDA receptor types. Memantine can be
thought of as use-dependent because it can only bind to open, active, NMDA receptors.
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Within the open channel blocker umbrella, there are three main delineations – 1) foot in
the door blockers prevent channel closure; 2) partial trapping blockers (memantine)
impede channel closure but are unable to completely prevent it; 3) trapping blockers
(ketamine) allow channel closure and agonist unbinding while being trapped in the
channel pore. While considered non-selective, memantine and ketamine show a 5-10
fold preference for GluN2C/D containing NMDA receptors (Kotermanski and Johnson,
2009). Memantine is approved by the FDA to treat mild to severe Alzheimer’s disease
and is well tolerated, possibly due to its relatively fast blocking/unblocking kinetics which
would result in reduced channel block during normal synaptic transmission (Chen and
Lipton, 2006).
Ifenprodil, a GluN2B selective antagonist, binds in the ATD dimer interface (i.e.
between GluN1 ATD and GluN2B ATD) (Karakas et al., 2009) and is hypothesized to
inhibit NMDA receptor activity by both stabilizing a desensitized state (Zhu et al., 2016)
and enhancing proton-mediated inhibition of NMDA receptor activity (Traynelis et al.,
1995; Pahk and Williams 1997)). Ifenprodil has been instrumental in illustrating GluN2Bcontaning NMDA receptor involvement in various physiological processes and was used
in a small clinical trial as an adjunct with L-DOPA to improve symptoms in Parkinson’s
patients, although no significant difference was found (Montastruc et al., 1992).

TCN-201, a GluN2A selective antagonist, binds in the ABD dimer interface (i.e.
between GluN1 ABD and GluN2A ABD) and acts to destabilize glycine binding (Yi et al.,
2016). Given this relationship, TCN-201 negatively modulates glycine binding and
glycine negatively modulates TCN-201 binding (Hansen et al., 2012). The MPX
compounds (Volkmann et al., 2016), a next-generation class of selective GluN2A
negative allosteric modulators (NAMs), have been characterized and show decreased
sensitivity to glycine and ability to inhibit GluN1/GluN2A/GluNB triheteromers, unlike
ifenprodil (Hansen et al., 2014).
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2.0 Characterization of NAM-mediated inhibition of NMDA receptors harboring GluN2A
gain-of-function mutations
2.1 Introduction
Glutamatergic synapses dictate the majority of excitatory neurotransmission in the
central nervous system and as such are intimately involved in physiological processes
ranging from neuronal survival to neurodevelopment and synaptic re-modeling. Within
the ionotropic glutamate receptor family, NMDA receptors act as coincidence detectors
to summate excitatory neurotransmission noise into binary all-or nothing signal
propagation. NMDA receptors require membrane depolarization to relieve a tonic Mg 2+
block and binding of both agonist and co-agonist at all four subunits in order to activate
a non-selective mono- and divalent cation channel that’s permeable to calcium
(Traynelis et al., 2010). In doing so, NMDA receptors translate chemical messages into
calcium influx to activate second messenger cascades that dictate the aforementioned
physiological processes.
During cortical neurodevelopment, postsynaptic NMDA receptors predominantly
express GluN1/GluN2B diheteromers (Monyer et al., 1994; Sheng et al., 1994), which
serve to initiate synaptic contacts among migrating and newly born neurons. As
development proceeds, GluN2A subunit expression commences and subunits are
subsequently trafficked to the membrane to join GluN1 and GluN2B-containing NMDA
receptors at postsynaptic densities (Tovar and Westbrook, 1999). Increasing prevalence
of GluN2A subunits confers synaptic refinement and general network maturation
(McKay et al., 2018), possibly by governing the dynamics of the excitatory postsynaptic
current.
This concept of GluN2B subunit dominance in synaptogenesis and GluN2A
subunit in synaptic refinement is bolstered by the finding that GluN2B knockout mice die
upon birth (postnatal day 0) (Kutsuwada et al., 1996), whereas GluN2A knockout mice
are viable and fertile into adulthood (Sakimura et al., 1995). Further, mutations in
GluN2B predominately manifest with intellectual disability (87% 101/116 patients) while
mutations in GluN2A present with both epilepsy (78% 78/100 patients) and intellectual
disability (70%) (XiangWei et al., 2017).
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Recently, due to advances in next-generation whole exome sequencing, the
gene encoding GluN2A (GRIN2A) has been implicated in the etiology of early-onset
epilepsy-aphasia spectrum (EAS) disorders including benign childhood epilepsy with
centrotemporal spikes, Landau-Kleffner syndrome, and epileptic encephalopathy with
continuous spike-and-wave during sleep syndrome. Benign childhood epilepsy with
centrotemporal spikes is the most prevalent (15-20%) focal epilepsy seen in children,
with an age of onset between 1-14 years (Watanabe et al., 2004) and characterized by
infrequent focal facial sensorimotor seizures during sleep with high-voltage focal spikes
in rolandic regions (i.e. the motor cortex). Approximately 50% of children with benign
epilepsy with centrotemporal spikes show seizure evolution to generalized tonic-clonic
seizures (bilateral synchronous sharp waves or sharp and slow wave complexes).
However, this seizure classification is considered benign because seizures remit in
adolescence with minimal alterations in language understanding and output.
Landau-Kleffner syndrome is considerably less prevalent with an occurrence of
about one in a million and general age of onset between 5-14 years. Similar to benign
childhood epilepsy with centrotemporal spikes, Landau-Kleffner syndrome can show
benign EEG patterns (i.e. focal epileptiform discharges) that transgress to aberrant
epileptiform events in nearly half of children with Landau-Kleffner syndrome.
Additionally, bilateral epileptiform discharges in the perisylvian cortex (cortex
surrounding the lateral sulcus – implicated in speech understanding and output) have
been documented in children with Landau-Kleffner syndrome (Paetau 2009). Children
with Landau-Kleffner syndrome live limited lives due to the resultant language and
overall cognitive difficulties and have poor prognoses.
Like Landau-Kleffner syndrome, the age of onset for epileptic encephalopathy
with continuous spike-and-wave during sleep syndrome is about 5 years old with
disease progressing into multifocal epileptiform discharges or bilaterally synchronous
spike and wave discharges that can last for more than 30 minutes. Seizures become
more frequent as the child ages and by about 1-2 years after onset, patients can
develop epileptic encephalopathy with status epilepticus during slow-wave sleep.
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Epileptiform activity dominates 85% of slow wave sleep and results in severe cognitive
deficits like those seen in Landau-Kleffner syndrome (Review - Lee et al., 2017).
In this work, we have selected six representative de novo (i.e. spontaneously
occurring, not inherited) GRIN2A mutations seen in children with EAS. We have
focused our studies on NMDA receptors containing GluN2A gain-of-function mutations,
though both loss and gain-of-function GRIN2A mutations have been implicated as the
monogenic cause in up to 20% of patients with severe EAS (i.e. Landau-Kleffner and
epileptic encephalopathy with continuous spike-and-wave during sleep syndromes).
These representative mutations are located throughout the agonist binding domains
(ABDs), linker regions between the ABD and transmembrane domains (TMDs), and one
at the apex of the M2 re-entrant loop of the TMD.
A male pediatric patient (17 years old) presenting with rolandic focal epilepsy
with centrotemporal spikes underwent whole-exome sequencing to reveal a GluN2AN447K mutation (Xu et al., 2018). His first seizure, generalized tonic-clonic, occurred at
nine years old and then he developed nocturnal rolandic epilepsy (bilateral high-voltage
spikes and spike and slow wave discharges in centrotemporal regions). Spike
discharges occupied about 50% of slow wave sleep which falls under the criteria for
rolandic epilepsy (a criteria of >80% is required to be classified as epileptic
encephalopathy with continuous spike-and-wave during sleep syndrome).
Diheteromeric NMDA receptors containing GluN2A-N447K mutation shows increased
current density, increased glutamate potency, and a reduction in Mg2+ block (Xu et al.,
2018).
A GluN2A-P552R mutation was detected in a female patient with severe
intellectual disability and seizure disorders (Ogden et al., 2017; de Ligt et al., 2002). Age
of seizure onset was 9 months and her development began slowing down at 3 months.
Speech was not developed, and she had severely delayed psychomotor development.
GluN2A-P552R is located in the pre-m1 linker region and NMDA receptors containing
GluN2A-P552R subunits have increased agonist potencies, channel open time,
deactivation kinetics, and sensitivity to Zn2+ inhibition (9nM vs 27nM in wild type
GluN2A containing NMDA receptors) (Ogden et al., 2017).
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A young female with a GluN2A-N615K mutation presented with epileptic spasms
and myoclonic seizures starting at 3 months of age, along with behavioral anomalies,
severe mental retardation, and muscular hypotonia (Endele et al., 2010). The GluN2AN615K mutation lies at the tip of the Mg2+ sensor in the M2 re-entrant loop and this
lysine replacement causes polar displacement of Mg2+ which results in insensitivity to
tonic Mg2+ block. This is considered gain-of-function because NMDA receptors
containing GluN2A-N615K mutations are more easily activated and have thus converted
from coincidence detectors to something more closely resembling calcium-permeable
AMPA receptors.
The GluN2A-K669N mutation, located in the ABD, was identified by a research
group who extracted data from the ExAC Browser (includes 60,706 exomes from
unrelated individuals) for missense variants in GluN2A and GluN2B subunits (Swanger
et al., 2016). The patient with a GluN2A-K669N mutation presented with epilepsy, and
NMDA receptors containing GluN2A-K669N subunits show increases in agonist
potencies, decreased open probability (0.04 compared to 0.18 seen in wild type GluN2A
containing NMDA receptors), and increased deactivation time course (Swanger et al.,
2016).
Both GluN2A-L812M and M817V mutations are located in the pre-M4 linker
region and the patients who harbor these mutations presented with early-onset epileptic
encephalopathy and severe developmental delay. NMDA receptors containing GluN2AL812M or M817V show increased agonist potencies, prolonged deactivation time
course, and increases in channel open time and probability (Yuan et al., 2014; Chen et
al., 2017). However, while these mutations are in close proximity, NMDA receptors with
GluN2A-L812M mutations are more sensitive to memantine (IC50 12µM) compared to
receptors with GluN2A-M87V subunits (IC50 30µM), which indicates that mutation
location does not predict drug interactions.
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Treatment strategies for children with EAS disorders generally include valproate
along with voltage-gated sodium channel blocker prescriptions, or in some cases,
memantine. These broad spectrum central nervous system depressants are not without
side effects, yet despite best efforts it has been difficult to find >10-fold selective
antagonists for GluN2A. Recently, GluN2A selective modulators were identified in a
Glaxo-Smith-Kline high-throughput screen campaign. It was found that these
compounds act as negative allosteric modulators (NAMs) of glycine binding to the
GluN1 subunit (TCN-201; Hansen et al., 2012) and, as with GluN2A positive allosteric
modulators, bind at the dimer interface between GluN1 and GluN2A subunits (Yi et al.,
2016; Hackos et al., 2016). More recent analogs (MPX-004 and MPX-007) have been
identified that are less sensitive to glycine than TCN-201 (Volkmann et al., 2016). These
GluN2A NAMs are completely selective for NMDA receptors containing GluN2A
subunits (Figure 2.1).
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Figure 2.1: Chemical structure and pharmacology of GluN2A-selective NAMs.
A) Chemical structures of GluN2A-selective negative allosteric modulators (NAMs).
B) Concentration-inhibition data for GluN2A-selective NAMs at recombinant NMDA
receptors. Adapted from Yi et al., 2016. Data are mean ± SEM from 4-11 oocytes

Here we have evaluated NAM binding and degree of inhibition during both
equilibrium and non-equilibrium states for NMDA receptors harboring wild type GluN2A
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or GluN2A subunits with gain-of-function mutations. We found that while the NAMs can
overcome increases in glycine potency seen in gain-of-function mutants, inhibition and
agonist potency are different in steady-state vs synaptic-like activation of NMDA
receptors. Furthermore, we have identified a gain-of-function mutant, GluN2A-P552R,
which causes a conformational change in the dimer interface that impedes NAM
binding.
2.2 Methods
2.2.1 RNA preparation and injection
Rat cDNAs for GluN1-1a (GenBank accession number U08261; hereafter GluN1)
and GluN2A (D13211) were provided by Drs. S. Heinemann and S. Nakanishi. For
expression in Xenopus oocytes, DNA constructs were linearized by restriction enzymes
and used as templates for in vitro cRNA transcription using the mMessage mMachine
kit (Thermo Fisher Scientific). Oocytes were purchased from Xenopus 1 and the follicle
layer was subsequently removed by treating the oocytes with 0.5 mg/ml collagenase
(type IA; Sigma-Aldrich) in OR-2 buffer (in mM: 82.5 NaCl, 2.0 KCl, 1.0 MgCl2, and 5.0
HEPES pH 7.6) at room temperature for 2-3 hours. cRNAs were combined at a ratio of
1:2 for GluN1 and GluN2 and diluted with RNase-free water to achieve desired
expression levels (i.e. recorded currents <10µA). Electrophysiological recordings were
performed 2–4 days after cRNA injection at room temperature (23 °C) and were
incubated at 17 °C (for 2-4 days) in modified Barth’s solution containing (in mM) 88
NaCl, 2.4 NaHCO3, 1 KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 0.82 MgSO4, and 5 Tris⋅HCl (pH
7.5 with NaOH) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin
(Invitrogen) as well as 50 mg/mL gentamicin (Fisher Scientific).

2.2.2 Two-electrode voltage clamp (TEVC) solutions and electrophysiology
Recordings were performed 2–5 days after cRNA injection at room temperature
(23°C) using a two-electrode voltage-clamp amplifier (OC725; Warner Instruments,
Hamden, CT). The signal was low-pass filtered at 20 Hz (4-pole, -3 dB Bessel;
Frequency Devices, Haverhill, MD) and digitized using PCI-6025E or USB-6212 BNC
data acquisition boards (National Instruments, Austin, TX). Oocytes were placed in a
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custom-made chamber and continuously perfused (approximately 5 ml/min) with oocyte
recording solution containing (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2, and 0.01
EDTA (pH 7.4 with NaOH). DMSO was controlled for each experiment and recording
electrodes were filled with 3 M KCl. Approximately 10-30 min before recordings, oocytes
were injected with 20-50 nL of 50 mM BAPTA to prevent activity-dependent increases in
response amplitude (Williams, 1994). Oocytes were voltage-clamped at -40 mV during
recordings. Glutamate (L-glutamic acid) and glycine were purchased from SigmaAldrich, TCN-201 from Hello Bio, and MPX compounds kindly supplied by Mnemosyne
Pharmaceuticals.
2.2.3 TEVC data analysis
Concentration-response data were analyzed using GraphPad Prism (GraphPad
Software v8). Data from individual oocytes were fitted to the Hill equation and fitted for
EC50 vaules:
I = Imax/(1 + 10^(logEC50 − log[A]) * nH))
Where Imax is the maximum current in response to the agonist, nH is the Hill
slope, [A] is the agonist concentration, and EC50 is the agonist concentration that
produces half-maximum response.
IC50 values:
I = Imin + (Imax – Imin)/(1+10^((log[A]-logIC50)*nH)), where Imin is the minimum current in
response to the agonist plus a saturating concentration of antagonist. Maximal inhibition
was calculated as 1-(Imin/Imax).
For graphing, data points were normalized to the maximum current response in
the same recording and the averaged data were then fitted to the Hill equation and
plotted together. For compounds evaluated using Schild analysis (Arunlakshana and
Schild, 1959), the glycine EC50 was measured in the absence of antagonist (TCN-201)
and EC50′ measured in the presence of increasing concentrations of TCN-201. These
values were used to calculate a dose ratio (DR= EC50′/EC50) for each TCN-201
concentration and log (DR - 1) was plotted versus TCN-201 concentration. The slope of
the Schild plot is 1 for a competitive antagonist according to the Schild equation: log
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(DR - 1) = pKi + log[B], where[B] is the antagonist concentration and pKi is the negative
logarithm of the antagonist concentration that produces a two-fold shift of the agonist
EC50 (i.e. Ki is the antagonist binding affinity).
Response = 1/(1+ (EC50′/[A])nH),
EC50′ = EC50(1 + [B]/KB)/(1+ α[B]/ KB),
Where [A] is the agonist concentration, [B] is the antagonist concentration, EC50
is for glycine in the absence of TCN-201, EC50′ is for glycine in the presence of different
concentrations of TCN-201, nH is the Hill slope, and KB is the dissociation constant for
TCN-201. All data are presented as mean ± SEM.
2.2.4 HEK293 cell culture and transfection
HEK-293 cells were cultured in Dulbecco’s Modified Eagle's Medium with
GlutaMax-I (Invitrogen) supplemented with 10% dialyzed FBS, 1 mM sodium pyruvate,
10 U/mL penicillin, and 10 µg/mL streptomycin and plated in 24-well plates on glass
coverslips coated with 0.1 mg/mL poly-d-lysine ∼48 h before the experiments. For
expression of GluN1/2A, cells were transfected with plasmid cDNAs encoding GluN1
and GluN2 subunits at a ratio of 1:2. We used the calcium phosphate precipitation
method as follows: to transfect four wells in a 24-well plate, 10 µl plasmid DNA (0.2
µg/µl; total 2 µg DNA) was mixed with 65 µl H2O and 25 µl 1 M CaCl2. This DNA-CaCl2
solution was then mixed with 100 µl 2 × BES solution composed of (in mM) 50 N,Nbis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 280 NaCl, 1.5 Na2HPO4 (pH
6.95 with NaOH), incubated for 12-15 minutes, and 50 µl of this solution (of the 200 µl
total) was then added dropwise to each of four 24-wells containing cells and 500 µl
culture medium. To minimize cytotoxicity, the culture medium was replaced 4–6 h after
transfection with medium containing NMDA receptor antagonists D,L-AP5 and 7-CKA
(200 µM each). Experiments were performed ∼24 h after transfection.
Whole-cell voltage-clamp recordings were performed using an Axopatch 200B
amplifier (Molecular Devices) at room temperature (23°C) with the holding potential at
−60 mV. Whole-cell currents were measured using pClamp10 (Molecular Devices) and
low-pass filtered at 20 Hz (4-pole, -3 dB Bessel; Frequency Devices, Haverhill, MD) and
digitized using PCI-6025E or USB-6212 BNC data acquisition boards (National
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Instruments, Austin, TX). Series resistance was compensated 85-90% with the
prediction and correction circuitry in all experiments. Electrodes were filled with internal
solution containing (in mM) 110 d-gluconate, 110 CsOH, 30 CsCl, 5 HEPES, 4 NaCl,
0.5 CaCl2, 2 MgCl2, 5 BAPTA, 2 NaATP, and 0.3 NaGTP (pH 7.35 with CsOH), and the
extracellular recording solution was composed of (in mM) 150 NaCl, 10 HEPES, 3 KCl,
0.5 CaCl2, 0.01 EDTA, 20 d-mannitol and 1 glutamate (pH 7.4 with NaOH). Rapid
solution exchange was achieved on lifted cells using a two-barrel theta-glass pipette
controlled by a piezoelectric translator (MXPZT-300; Siskiyou Corporation, Grants Pass,
OR), and the speed was measured to be 0.4-0.8 milliseconds (10%–90% rise times)
from the open tip junctional potential. Only cells with current responses of less than 1
nA were recorded to prevent inaccurate measurement of decay time courses due to
poor resistance compensation.

2.2.5 Whole cell recording data analysis
Whole-cell patch-clamp recordings were analyzed using AxoGraph
(www.axograph.com) to determine response rise time, deactivation kinetics (fit with
either mono or dual exponential equations), and current amplitude. The deactivation
time courses of current responses (each averaged from at least five sweeps) were fitted
using:
Itotal = Ifast (−time/τfast) + Islow(−time/τslow)
where τfast and τslow are the deactivation time constants for the fast and slow
components, respectively, and Ifast and Islow are the current amplitudes of the fast and
slow components, respectively. Weighted deactivation time constants were calculated
using:
τweighted = τfast(Ifast / Ifast + Islow) + τslow(Islow / Ifast + Islow)
Response amplitudes and τweighted time constants were plotted in GraphPad
Prism (GraphPad Software v8). Data are presented as mean ± SEM. One and two-way
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ANOVAs with Tukey post-hoc test were used for statistical comparisons as indicated
and p < 0.05 was considered significant.
2.3 Results
To investigate functional and pharmacological properties of NMDA receptors
containing GluN2A gain-of-function mutations, we selected six mutations identified in
children with epilepsy-aphasia spectrum (EAS) disorders. Mutations are located in the
agonist binding domain (ABD), linker regions between the ABD and transmembrane
domains (TMD), or the M2 reentrant loop of the TMD (Figure 2.2). While these
mutations had previously been characterized as gain-of-function, many properties have
yet to be determined for all six mutants.
Glutamate and glycine concentration-response data were measured using twoelectrode voltage-clamp (TEVC) recordings on Xenopus oocytes injected with GluN1
and GluN2 wild type or mutant mRNA. All GluN2A gain-of-function containing NMDA
receptors showed increased agonist and co-agonist potencies, except for GluN2AN615K (Figure 2.2). GluN2A-N615K to behave like wild type GluN1/2A receptors, which
is to be expected as the N-to-K mutation relieves sensitivity to Mg2+ block, which has not
been found to modulate agonist binding and gating properties (Endele et al., 2010;
Pierson et al., 2014). Data are summarized in Figure 2.2C and NMDA receptors
containing GluN2A mutations (except for GluN2A-N615K) have significantly increased
agonist and co-agonist potencies as compared to wild type GluN1/2A.
The GluN2A-selective negative allosteric modulators (NAMs) bind at the dimer
interface between GluN1-GluN2 subunits and act to destabilize glycine binding in GluN1
subunits (Yi et al., 2016). It was unknown whether NAM binding could overcome
increases in glycine potency seen in GluN2A gain-of-function mutants. We sought to
determine NAM binding potencies in the presence of 3 µM glycine for the six gain-offunction mutations using TEVC recordings at recombinant wild type or mutant NMDA
receptors. NAM concentration response curves mirrored the trend in agonist and coagonist EC50 seen in Figure 2.2, with wild type and GluN2A-N615K being the most
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Figure 2.2: Characterization of NMDA receptors containing GluN2A gain-offunction mutations A) Linear and modular representation of a GluN2A subunit with
locations of gain-of-function mutations (stars) overlaid. NMDA receptor subunits
contain an amino-terminal domain (ATD), agonist binding domain (ABD),
transmembrane domain (M1-M4), and carboxy-terminal domain (CTD). B) Glycine
(left) and glutamate (right) concentration-response curves in the continuous
presence of 100µM glutamate or glycine, respectively. C) Summary of agonist
potencies. Data are mean ± SEM from 4-7 oocytes. *Indicates significantly different
from GluN1/GluN2A (p<0.05 one-way ANOVA corrected for multiple comparisons
with a Tukey post-hoc test)
sensitive, GluN2A-K669N as an intermediate, and GluN2A-N447K, P552R, L812M, and
M817V as the least sensitive to NAM-mediated inhibition (Figure 2.3).
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Figure 2.3: Inhibition by GluN2A-selective NAMs. A) Representative traces
showing concentration-dependent inhibition by MPX-004 for GluN2A wild type (left)
and GluN2A-P552R (right). B) NAM concentration-response curves. TCN-201 (left)
is maximally soluble at 5µM, MPX-004 10µM (middle), and MPX-007 30µM (right).
For each NAM, data are mean ± SEM from 5-17 oocytes.
To further probe the reciprocal relationship between glycine and NAM binding,
we plotted glycine EC50 against TCN-201 IC50 (in the presence of 3 µM glycine) and
performed a Pearson’s correlation test (Figure 2.4). We found that the data are highly
orrelated (R2 = 0.98) if GluN2A-P552R is excluded from correlation analysis. When
GluN2A-P552R values are included, the correlation is less correlated, with a fit of R2 =
0.80. This indicates that decreased NAM-mediated inhibition of NMDA receptors
containing GluN2A-P552R subunits cannot be fully described by increases in glycine
potency.
Due to the disparity in NAM IC50 vs glycine EC50 correlation seen in NMDA
receptors containing GluN2A-P552R mutations, we sought to delineate whether this
difference is due to alterations in NAM binding affinity (Kb) or the negative allosteric
relationship between NAM and glycine binding (α). In our operational model, the
dissociation constant for agonist binding (Ka) is modulated by a factor of 1/ α, where α is
the allosteric constant, and accordingly antagonist binding (Kb) is modulated by the
same factor upon agonist binding (Christopoulos and Kenakin 2002). We assume that
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the negative, reciprocal relationship between NAM and glycine binding doesn’t affect
glutamate and glycine agonist efficacies (Figure 4A) (i.e. NAM destabilization of glycine
binding doesn’t affect channel conductance or open probability). Negative allosteric
modulation is defined as 0 < α <1, neutral modulation alpha = 1, positive α>1, and
competitive inhibition α=0, as is the case for the canonical Schild equation.
Furthermore, the dose ratio (DR) is defined as the ratio of EC50 values in the presence
and absence of antagonist (EC50 ‘).
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Figure 2.4: Correlation between glycine and NAM potencies. A) Increases in
glycine potencies seen in NMDA receptors containing GluN2A gain-of-function
mutations correlate with decreases in NAM potency, except for GluN2A-P552R. B)
NMDA receptor crystal structure (PDB ID 4PE5) with TCN-201 (red), glutamate and
glycine (blue), and GluN2A gain-of-function mutation locations indicated (black).
We performed Schild analyses of glycine concentration-response curves in the
increasing presence of TCN-201 (Figure 2.5) and fit the all the data using a global
nonlinear regression model (Hansen et al., 2012). Using this analysis for wild type
GluN1/2A c receptors, we arrived at a TCN-201 binding affinity (Kb) equal to 17nM with
an allosteric constant of 0.004, indicating that TCN-201 can at most cause a 250 (1/α)
fold increase in glycine EC50 (i.e. increase glycine potency from 1µM to 250µM).
To determine possible differences in binding affinity or allosteric interactions, we
then repeated Schild analyses on select representative GluN2A gain-of-function
containing NMDA receptors (GluN2A-N615K, GluN2A-L812M, GluN2A-P552R). While
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Figure 2.5: Evaluation of allosteric inhibition of GluN2A-containing NMDA
receptors. A) Operational model of allosteric inhibition without altering receptor
efficacy (E). A is agonist, R is receptor, and B is antagonist. Dissociation constants
for agonist (Ka) and antagonist (Kb) are modulated by the allosteric constant (α),
which reflects the reciprocal relationship between glycine and NAM binding. B)
Glycine concentration-response curves in the presence of increasing concentrations
of TCN-201. Dose-response data are simultaneously fitted to the Hill and dose ratio
(DR) equations using global nonlinear regression (left). TCN-201 binding in the
absence of glycine is calculated at 17.2 ± 0.002 nM with an allosteric constant of
0.004 ± 0.002. The Schild plot (right) illustrates the difference in allosteric constants
of a competitive inhibitor (α=0) and TCN-201 (α=0.004). Data are mean ± SEM from
4-6 oocytes, repeated on three separate days, for a total of 12-24 oocytes for each
glycine response-curve.
Kb and α values for GluN2A-N615K and GluN2A-L812M are similar to wild type
GluN1/2A, NMDA receptors containing GluN2A-P552R have a markedly different
binding affinity and allosteric constant (Figure 2.6). This indicates that NMDA receptors
harboring GluN2A-P552R mutations have a conformationally distinct dimer interface
(i.e. where GluN2A-selective NAMs bind) in comparison to wild type GluN1/2A
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Figure 2.6: Schild analysis of NMDA receptors containing GluN2A gain-offunction mutations. Glycine concentration responses curves in the presence of
increasing concentrations of TCN-201 for GluN1-a/GluN2A-N615K (A), GluN1a/GluN2A-L812M (B), and GluN1-a/GluN2A-P552R (C), left. Schild plots are
plotted against GluN1-a/GluN2A wild type (right). GluN1-a/GluN2A-P552R TCN201 binding affinity is increased by 10-fold (C). Data are mean ± SEM from 4-6
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12-24 oocytes for each glycine response-curve.
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receptors. Therefore, a mutation in the pre-m1 linker region transduces a
conformational change in the dimer interface, which was unexpected.
Since synaptic transmission occurs in the millisecond timescale, we sought to
characterize kinetics of activation, deactivation, and the extent of NAM-mediated
inhibition during brief exposures to glutamate suing whole-cell patch-clamp recordings.
HEK293 cells transfected with GluN1-GFP and GluN2A wild type, or mutant subunits,
were exposed to 1mM glutamate for 3-5ms in the continuous presence of 10 µM glycine
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Figure 2.7: Kinetic properties during synaptic-like activation of NMDA
receptors with GluN2A gain-of-function mutations. Representative traces
normalized to response amplitude of GluN1/GluN2A NMDA receptors with synapticlike pulses of glutamate, in the continuous presence of 10µM glycine. A)
GluN1/GluN2A wildtype, N615K, and K669N deactivate on a faster timescale as
compared to B) N447K, P552R, L812M, and M817V-containing NMDA receptors. C)
Summary of deactivation kinetics and D) rise time to peak amplitude of wild type
GluN1/GluN2A and all six mutants. Data are mean ± SEM from 13-33 HEK293T
cells
(Figure 2.7). All mutant subunits, except GluN2A-P552R, had comparable rise times as
seen in wild type GluN1/2A (Figure 2.7D). Conversely, NMDA receptors harboring
GluN2A-N447K, P552R, K669N, L812M, or M817V subunits had prolonged deactivation
kinetics (Figure 2.7B & C).
We then assessed glycine sensitivity and NAM-mediated inhibition at both low
and intermediate physiological levels of glycine (i.e. 0.3 and 3µM, respectively). We
found that increases in glycine potency (i.e. lower EC50 values compared to wild type,
see Figure 2.2) measured using TEVC recordings during steady-state for receptors with
GluN2A-N447K, P552R, K669N, L812M, or M817V subunits were not observed in
synaptic-like activation experiments (Figure 2.8 A&D). Instead, NMDA receptors
harboring gain-of-function mutations showed similar response ratios to 0.3 and 10µM
glycine as NMDA receptors expressing GluN2A wild type subunits (Figure 2.8A & D),
albeit except for GluN2A-P552R mutants. Similarly, 3µM NAM was able to fully inhibit
NMDA receptors containing GluN2A gain-of-function subunits, except for those
containing GluN2A-P552R subunits. NMDA receptors with GluN2A-P552R subunits
were most sensitive to 3µM MPX-004 and 007 (68 and 74% inhibition, respectively) as
compared to TCN-201 (45% inhibition) (Figure 2.8B & E).

39

1mM glutamate
application

A

0.3 µM Gly
1 sec

10µM Gly
WT

Mutant

Mutant

GluN1/N2A

GluN1/N2A-L812M

GluN1/N2A-P552R

B

C

TCN-201

MPX-004

3µM Gly + 3µM NAM
3µM Gly
10µM Gly
Mutant

WT

GluN1/N2A

GluN1/N2A-P552R

Mutant

GluN1/N2A

GluN1/N2A-P552R
TCN-201
MPX-004
MPX-007

E

*

0.3M Gly
3M Gly

100

% inhibition

1.0

0.5

50

40

P5
52
R
N
61
5K
K6
69
N
L8
12
M
M
81
7V

N

W

T

P5
52
R
N
61
5K
K6
69
N
L8
12
M
M
81
7V

44
7K

T
W

44
7K

0

0.0

N

normalized response
(% 10M glycine)

D

WT

Figure 2.8: Agonist and NAM potencies during synaptic-like activation of
NMDA receptors harboring GluN2A gain-of-function mutations. A)
Representative whole cell recordings of responses elicited by brief glutamate
exposure (1 mM for 3-5ms) in the continuous presence of 0.3 or 10 µM glycine for
NMDA receptors containing GluN2A-WT (left), -L812M (center), and –P552R (right).
B) Representative recordings in mid-range physiological glycine and extent of 3 µM
TCN-201 or C) MPX-004 inhibition in GluN2A-WT or –P552R containing NMDA
receptors. D) Summary plot of 0.3 and 3 µM glycine response normalized to 10 µM
glycine. E) Summary plot of 3 µM NAM inhibition in 3 µM glycine for all mutants. Data
are mean ± SEM from 4-10 HEK293 cells. *Indicates significantly different from
GluN1/GluN2A ratio of 0.3 to 10 µM glycine (p<0.05 one-way ANOVA corrected for
multiple comparisons with a Tukey post-hoc test).
2.4 Discussion
In this work, we have assessed the extent to which GluN2A-selective NAMs can
inhibit NMDA receptors containing GluN2A gain-of-function mutations identified in
children with epilepsy-aphasia spectrum (EAS) disorders. This is a proof-of-concept
study aimed at answering whether GluN2A-selective NAMs could potentially be a viable
therapeutic strategy to target and ameliorate hyperactive GluN2A-containing NMDA
receptors. Children with EAS are prescribed general central nervous system
depressants to treat severe epilepsy during slow-wave sleep, and theoretically could
benefit from a more targeted approach with fewer off-target effects.
NMDA receptors harboring GluN2A subunits with gain-of-function mutations
show various forms of gain-of-function attributes, including increased agonist potencies,
decreased sensitivity to endogenous inhibitors, and increases in channel open time and
open probability (Endele et al., 2010; Yuan et al., 2014; Swanger et al., 2016; Chen et
al., 2017; Ogden et al., 2017; Xu et al., 2018). First, we characterized differences in
glutamate and glycine potency under steady-state conditions using two-electrode
voltage-clamp electrophysiology. We found that, with the exception of GluN2A-N615K
mutants, all NMDA receptors with GluN2A gain-of-function mutations have both
increased glutamate and glycine potencies (Figure 2.2).
Since GluN2A-selective NAMs inhibit NMDA receptor activation by destabilizing
glycine binding, it was unknown whether these NAMs could overcome increases in
glycine potency seen in the gain-of-function mutants. GluN2A-N615K NMDA receptors
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served as our positive control because the only gain-of-function feature of these
receptors is a Mg2+ relief, which we did not predict to affect NAM binding or inhibition.
We found that all NMDA receptors containing GluN2A gain-of-function mutations were
inhibited by NAMs, but with reduced NAM potencies that reflected increases in glycine
potency (i.e. receptors with increased glycine binding show decreased NAM binding).
To assess possible differences in correlation between NAM and glycine binding, we
analyzed the relationship between glycine EC50 vs TCN-201 IC50 (in 3µM glycine)
(Figure 2.4). We found that all mutants showed high correlation (R2 = 0.98) between
glycine EC50 and TCN-201 IC50 except for NMDA receptors harboring GluN2A-P552R.
Inclusion of GluN2A-P552R agonist and NAM potency into our correlation plot shifted
the Pearson correlation fit from 0.98 to 0.8. This indicates that the GluN2A-P552R
mutation may disrupt NAM binding or the allosteric association between NAM and
glycine destabilization.
Using Schild analysis of glycine concentration-response curves in the presence
of increasing antagonist (TCN-201), we calculated antagonist binding affinity (KB) in the
absence of glycine, along with the allosteric constant, which quantifies the negative
relationship between NAM and glycine binding (Figure2.5). In addition to wild type
GluN2A containing NMDA receptors, we performed these experiments on a subset of
the representative mutants, including GluN2A-N615K, L812M, and P552R (Figure 2.6).
We found that NMDA receptors harboring GluN2A-P552R subunits have a 10-fold
decrease in NAM binding affinity, indicating that this mutation causes a conformational
change in the dimer interface where NAMs bind. All other mutants showed unaltered
antagonist binding affinities (Figure 2.6).
Since synaptic events occur on a millisecond timescale, we assessed kinetic
properties of GluN2A gain-of-function mutants, agonist sensitivity, and NAM-mediated
inhibition under non-equilibrium conditions in both low (0.3 µM) and intermediate (3 µM)
estimates of physiological glycine to characterize potential differences in NAM
sensitivities to glycine. HEK293 cells transfected with GluN1 and GluN2A subunits, with
or without gain-of-function mutations, were activated by brief (3-5ms) pulses of
glutamate in the continuous presence of glycine with or without 3 µM NAM.
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In the absence of NAM, the amplitude ratio of 0.3 and 3 µM glycine to 10 µM
glycine was equivalent to the ratios at wild type GluN1/2A receptors for all gain-offunction mutants, except NMDA receptors containing GluN2A-P552R subunits (Figure
2.8). Therefore, the increases in glycine potency measured during equilibrium
conditions do not reflect those seen in non-equilibrium conditions in NMDA receptors
harboring GluN2A gain-of-function mutations.
The lack of agreement between glycine potencies in equilibrium and nonequilibrium measurements could be attributed to the presence and absence,
respectively, of NMDA receptor desensitization during the measurements. During
equilibrium or long exposure to agonist, NMDA receptors can desensitize, which results
in channel closure while agonists are still bound. As receptors exit the desensitized
state with bound agonist, they can either re-enter the desensitized state, enter the open
state, or the agonists can unbind (Figure 2.9). The desensitized state therefore acts as
a conformational “sink” that effectively slows agonist unbinding. Consequently, the
agonist potency (i.e. apparent affinity) will be higher in the presence of desensitization
compared to in the absence of desensitization.

2A + R

2kon
koff

A + AR

β

kon
2koff

A2R
kr

kd

O*
α

A2D

Figure 2.9: Fundamental kinetic model of NMDA receptor activation and
deactivation. The receptor, R, has two binding sites for agonist, A. O* is the open
channel state while A2D is the desensitized state. β and α represent the opening and
closing rates, kon and koff the binding and unbinding rates, and kd and kr are the rates
of desensitization and resensitization. Adapted from Lester and Jahr 1992.
Despite differences in glycine potency between steady-state and synaptic-like
activation, all mutants, except for our positive control (GluN2A-N615K), displayed
prolonged deactivation time courses compared to wild type receptors (Figure 2.7).
Therefore, while nearly all gain-of-function mutants showed reduced sensitivity to
glycine during synaptic-like events, gain-of-function attributes may be reflected in total
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charge transfer. Furthermore, increases in open probability (i.e. increased agonist
efficacy) were not assessed but would also contribute to gain-of-function properties.
All gain-of-function containing NMDA receptors, except those harboring GluN2AP552R subunits, were fully inhibited by 3µM TCN-201, MPX-004, and MPX-007. The
greater extent of NAM inhibition under synaptic-like events reflect the data seen with
apparent decreases in glycine potency. These data could be explained by a lack of
NMDA receptor desensitization and therefore an apparent decrease in glycine potency
and an increase in NAM potency fit well together. To assess desensitization
contribution, future experiments should be centered on longer agonist and NAM
exposure to determine differences in peak and steady-state response amplitudes.
Together, these data support the dimer interface between GluN1 and GluN2A
subunits as an attractive therapeutic target for GluN2A gain-of-function disorders. Of the
six representative gain-of-function mutants tested, only one caused changes in the
dimer interface. This indicates that most GluN2A gain-of-function mutations do not alter
the conformation of the dimer interface, which allows NAMs to inhibit a wide-range of
gain-of-function phenotypes. Furthermore, despite the reduced binding affinity, NAMs
were still able to inhibit NMDA receptors containing GluN2A-P552R subunits.
Additionally, NAMs were more effective inhibitors in physiological time-scales (i.e.
synaptic-like events), which further purports the dimer interface as an attractive
therapeutic target to ameliorate hyperactive NMDA receptors containing GluN2A gainof-function mutations.
3.0 Quantification of excitotoxicity in cortical neurons transfected with GluN2A gain-offunction mutations

3.1 Introduction
The subunit composition of NMDA receptors is tightly regulated both temporally
and spatially, which imparts a high degree of NMDA receptor pharmacological diversity
during development. During development of the cortex, GluN2A subunit expression
gradually increases and integrates into the synapse (Monyer et al., 1994; Sheng et al.,
1994). This developmental switch also occurs in vitro during rodent primary cortical cell
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and organotypic culture development, where GluN2A expression begins postnatally
around day in vitro (DIV) 7 and extends through 21 (Li et al., 1998; Barria and Malinow,
2002).
As GluN2A subunits integrate into the synapse, triheteromeric
GluN1/GluN2A/GluN2B receptors become more prevalent. Triheteromeric receptors do
not simply adopt intermediate properties between diheteromeric GluN1/GluN2A and
GluN1/GluN2B NMDA receptors. Instead, GluN1/GluN2A/GluN2B receptors show
kinetic properties dominated by GluN2A (i.e. faster decay kinetics and increased open
channel probability) (Sun et al., 2017). GluN2A subunit expression is biologically
documented as a developmental switch to associative learning (Dumas 2005). Indeed,
GluN2A knock-out mice show altered synaptic plasticity and impaired learning
(Andreescu et al., 2011; Sakimura et al., 1995; Zhao and Constantine-Patron, 2007).
This indicates that GluN2A expression is important for time-sensitive synaptic
integration of sensory inputs.
Due to GluN2A’s role in dictating the kinetic window for associative learning, it is
no surprise that gain or loss-of-function mutations in GluN2A cause disruptions in
learning processes. In fact, the etiology of certain severe forms of epilepsy-aphasia
spectrum (EAS) disorders are associated with de novo missense mutations in GluN2A.
Pediatric patients with EAS have seizures during sleep, which can result in speech
impairments and, in severe cases, general intellectual disability with developmental
delay (XiengWei et al., 2018).
Recently, Strehlow and colleagues (2018) have found a correlation between the
location of GluN2A mutations and their impact on disease severity. They assessed a
cohort of 248 individuals, 92 of which were from unpublished screens and another 156
from previous reports. Both groups were identified to have “likely” pathogenic variants
for which the criteria includes: de novo mutations absent in controls, novel missense
mutations located in a genomic region already classified as “pathogenic” where
variation is absent in controls, confirmative functional studies that are in disagreement
from controls, or mutations present in three or more members of a family but are absent
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from controls (controls were over 120,000 people without severe pediatric disease
gathered from gnomAD.broadinstitute.org).
In their cohort, sex was divided similarly among variants (45% female, 55%
male). The youngest individual was 11 months old and the eldest was 71 years old, with
a median age of eight years. Nearly half of the cohort had de novo GRIN2A (gene
encoding GluN2A) mutations, the rest belonging to familial inheritance from 36 different
families (127 individuals). 62% of individuals showed intellectual disability, 88%
presented with epilepsy, 92% had speech disorders, and interestingly, 75% of
individuals had no MRI abnormalities. They then identified phenotypic correlations when
separating the cohort into individuals with mutations in the transmembrane domain
(TMD) or linker regions from those with mutations in the agonist binding domain (ABD)
or amino-terminal domain (ATD). Individuals with mutations in the TMD or linker region
show more severe intellectual disability than those with mutations in the ABD or ATD.
Furthermore, individuals with documented brain volume loss on MRIs had mutations in
either the TMD or linker regions, whereas individuals with a mutation in the ABD or ATD
showed no volume loss. Both groups showed similar EEG patterns but individuals with
mutations in the TMD or linker regions presented with epileptic spasms, whereas
individuals with mutation in the ABD or ATD were more likely to present with focal
seizures (Strehlow et al., 2018).
Here, we sought to characterize cellular toxicity associated with expression of
GluN2A gain-of-function mutations located in the TMD and linker regions. As these
mutations cause central nervous system atrophy in humans, we hypothesized that
transfection of these GluN2A gain-of-function mutants would be neurotoxic. Along this
rationale, Ogden and colleagues (2017) transfected neurons in culture with GluN2AP552R (pre-m1 linker region) subunits, which caused significant neural blebbing, a
precursor of neural cell death. Furthermore, they were able to rescue GluN2A-P552R
mediated cell death by concomitant treatment with memantine, a non-selective NMDA
receptor open channel blocker.
We have found that all gain-of-function transfected cells show a slight increase in
blebbing compared to GluN2A-WT controls, and one mutant, GluN2A-L812M, caused
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significantly increased blebbing. However, this minimal blebbing was unable to be
rescued by GluN2A-selective allosteric modulators (NAMs) or memantine. We conclude
that excitotoxicity, measured through neurite blebbing, is not a direct consequence of
NMDA receptors containing GluN2A gain-of-function mutants.
3.2 Methods
3.2.1 Coverslip preparation
Glass coverslips of 12mm in diameter (Fischer Scientific) were shaken (200
rotations per minute) overnight, while immersed in sand to facilitate etching. The
following day, coverslips were washed three times with sterile water and then lightly
agitated with 1M HCl overnight to remove grease. The next day, coverslips were
washed three times with sterile water followed by a final wash with 80% ethanol and
then were left overnight in the tissue culture hood to dry.
Coverslips were moved to 24-well plates a couple days before dissection and
incubated in 80% ethanol for 20 minutes. Coverslips were then washed three times with
sterile Hanks’ Balanced Salt Solution – Ca2+ and Mg2+ (HBSS-, Life Technologies)
before being coated in 0.2mg/mL high molecular weight poly-D-lysine (70-150kDa,
Sigma) dissolved in 0.22µm filtered 1M borate buffer (pH 8.7). Plates containing glass
coverslips were incubated overnight (370C, 5%CO2) and then washed three times with
HBSS-. Plates were then incubated in 10µg/mL laminin (R&D Systems, Culturex Mouse
Laminin I PathClear®) in ice-cold HBSS- in a 40C refrigerator until needed (up to a
month).
3.2.2 Mouse brain dissection and plating
Postnatal day 0-1 (P0-1) C57BL/6 mice of either sex were decapitated in
accordance with the Institutional Care and Animal Use Committee and Department of
Laboratory Animal Resources at the University of Montana. The brain was rapidly
dissected and promptly emerged in ice-cold Hibernate AB complete media (Brain
Bits®). Following dissection of hippocampi or cortices, tissues were incubated in 140
units of papain (Worthington Biochemicals) dissolved in Hibernate A minus calcium
(BrainBits®) at 370C for 20 minutes while shaking at 450 rotations per minute. A
maximum of two pairs of hippocampi and one pair of cortices were incubated in 140
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units of papain, preparations were scaled according to amount of tissue being
processed.
Following digestion with papain, tissue was moved to a 15mL conical tube
containing room temperature Hibernate AB complete media (Brain Bits®). Tissue was
triterated ten times with a glass Pasteur pipette then left for three minutes to allow the
tissue to settle to the bottom of the tube. The supernatant containing single cells was
collected and moved to another 15mL conical tube. This process was repeated three
times, then the cell suspensions were spun down at 1100 rpm (200 x g) for 3 minutes at
room temperature. Supernatant was removed and cells were resuspended in 1mL of
neuronal NBCo-Culture media (BrainBits®) containing 25µM sterile-filtered 10mM
glutamate and 1x Penicillin/Streptomycin (Life Technologies). Cell counts were
performed by combining 10 µL cell suspension and 10 µL trypan blue solution
(Invitrogen) and plated at a density of 2e5 cells/mL. A 100% media change was
performed 24 hours after plating with NBCo-Culture with 25 µM glutamate. Half of the
media was changed four days later with NBCo-Culture media. Another complete media
change is performed at day in vitro (DIV) 8-9 with NBActiv4 (BrainBits®) and 50%
media changes are maintained every four days, or earlier if the media becomes acidic
(i.e. turns yellow).
3.2.3 Neuronal transfection
On DIV17 primary neuronal cultures were transfected with Neuromag (OZ
Biosciences®). For each well of a 24-well plate, 100 µL of NBActiv4 was combined with
0.75 µg DNA. DNA, prepared with endotoxin-free maxi-prep kits (Qiagen®), included
green-fluorescent protein (GFP), wild type GluN2A, GluN2A-N615K, GluN2A-L812M,
and GluN2A-P552R, all driven by a calcium-calmodulin kinase promoter. GFP and
GluN2A subunits were combined in 1:1 ratio for a total of 0.75 µg DNA/well. DNA and
NBActiv4 solution was then combined with 1.5 µL Neuromag and let to incubate at room
temperature for 20 minutes. After incubation, the plate was moved to the magnetic plate
and incubated for 20 minutes (370C, 5%CO2) before removing the magnetic plate from
the tissue culture incubator. After 4-6 hours following transfection, media was removed
and half was aliquoted and combined with fresh NBActiv4 with either vehicle (0.1%
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DMSO), 3 µM MPX-007, 30 µM MPX-007, or 50 µM memantine (DMSO controlled in all
conditions). Three days following transfection, neurons were fixed in 4%
paraformaldehyde and moved to a 40C refrigerator until further processing (up to a
week).
3.2.4 Preparation of slides for microscopy
Paraformaldehyde was removed from 24-well plates containing neuron-coated
coverslips and washed three times with HBSS containing Ca2+ and Mg2+ (Life
Technologies). Coverslips were then plated on slides (Shandon ColorFrost Plus,Thermo
Fisher Scientific) with DAPI Vectaschield mounting medium (Vector Laboratories) and
sealed with clear nail polish. Slides were stored in a 40C refrigerator until processing.
3.2.5 Confocal imaging and analysis of neuronal cultures
Neurons were imaged using a Zeiss® 880 confocal laser scanning microscope
(Zeiss LSM 880). Images were obtained at 20x magnification and z-stacks were
established to have 50% overlap between 0.88µM sections. Z-stacks were analyzed by
performing a maximum intensity projection (Fiji). The image was then converted into a
binary bit image by setting the threshold to 2x the background noise. Neuronal blebbing
was then quantified using the “analyze particles” feature in Fiji. Two measurements
were taken using this plug-in feature, the first being the total cell area (0-infitie µM;
circularity 0-1), and the second quantifying neural cell blebbing (3-infitie µM; circularity
0.35-1).
Percent blebbing was calculated as the ratio of the total blebbing area to the total
cell area. Only neurons showing at least three branch points were included for analysis.
Values were plotted using Prism8® (GraphPad) and data were analyzed using one-way
ANOVA with mutants compared to wild type, followed with a Tukey post-hoc test and
regarded as significant if p<0.05.
3.3 Results
In this work we sought to characterize cellular toxicity resulting from transfection
of GluN2A gain-of-function mutants. We were able to detect expression of subunits in
excitatory cells by use of plasmids containing green fluorescent protein (GFP) or
GluN2A subunits, both driven by a calcium-calmodulin kinase (CaMKII) promoter. As
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CaMKII is only expressed in excitatory neurons in the hippocampus (Jones et al., 1994),
we were able to ask whether expression of mutated GluN2A subunits mediate
excitotoxicity in cultured excitatory neurons. We isolated cortical neurons from postnatal
day 0-1 (P0 -1) mice and cultured neurons for a total of 20 days, with transfection of
relevant subunits on day in vitro 17 (DIV 17) (Figure 3.1A). After transfection, neurons
were incubated in the presence or absence of MPX-007, or memantine, to protect
neurons from potential cytotoxicity caused by GluN2A gain-of-function mutants.
All gain-of-function mutants showed a minimal increase in neurite blebbing
compared to GluN2A-WT transfected controls, though only toxicities resulting from
GluN2A-L812M transfections were considered significant (Figure 3.1B & C) (GluN2AWT 0.5 ± 0.2%, GluN2A-P552R 2.0 ± 0.5%, GluN2A-N615K 2.5 ± 0.5%, GluN2AL812M 2.8 ± 0.5%, one-way ANOVA with Tukey post-hoc test; p < 0.05). Furthermore,
this significant increase in cellular toxicity by transfection of GluN2A-L812M subunits
could not be rescued by NAM or memantine treatment (Figure 3.1B & C).
Though the blebbing quantified in GluN2A-P552R transfected cells did not show
significantly different blebbing compared to GluN2A-WT transfected cells, the moderate
increase in blebbing was significantly reduced by both 3 and 30 µM MPX-007 (0.4 ±
0.1% and 0.2 ± 0.1%, respectively; one-way ANOVA with Tukey post-hoc test; p < 0.05)
(Figure 3.1B & C). Similarly, 3 µM MPX-007 showed moderate protection against
blebbing in GluN2A-L812M (1.9 ± 0.5%), but not GluN2A-N615K (2.2 ± 0.4%)
transfected cells (Figure 3.1B & C). The opposite trend was seen for 30 µM MPX-007
where there was a moderate rescue in in GluN2A-N615K (1.5 ± 0.4%), but not GluN2AL812M (2.5 ± 0.6%) transfected cells.
While 50 µM memantine had no significant effect on ameliorating moderate
cytotoxicity seen in GluN2A gain-of-function transfections, there is a trend in decreasing
cell blebbing in GluN2A-P552R and GluN2A-L812M transfected neurons (GluN2AP552R 0.6 ± 0.2% and GluN2A-L812M 1.5 ± 0.4%) As we expected, memantine
showed no trend in protecting neurons harboring GluN2A-N615K mutations (GluN2AN615K 2.0 ± 0.9%). This served as our negative control because the N-to-K mutation
prevents positively charged species, like memantine, from binding in the channel pore.
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Together, these data suggest that toxicity associated with GluN2A gain-offunction mutations cannot be explained by a straight-forward mechanism that involves
excitotoxicity. These gain-of-function mutations were solely expressed in excitatory
neurons, due to expression being driven by a CaMKII promoter, and yet did not cause
significant blebbing, except for GluN2A-L812M. Therefore, the gain-of-function
attributes seen in NMDA receptors harboring these mutations do not promote neuronal
cell death due to excitotoxicity.
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Figure 3.1: Measurement of excitotoxicity in cortical neurons expressing
GluN2A gain-of-function mutants. A) Timeline of cortical neuron isolation, culture,
and transfection. B) Representative images of mature cortical neurons transfected
with GFP and GluN2A-WT or GluN2A gain-of-function subunits. Following
transfection, neurons were either incubated in 0.1% DMSO, 3 or 30 µM MPX-007, or
50 µM memantine. C) Summary plots quantifying neural blebbing normalized to total
cell area. GluN2A-L812M subunits showed significant blebbing compared to neurons
transfected with GluN2A-WT subunits. *Indicates significantly different from
GluN1/GluN2A neurite blebbing (p<0.05 one-way ANOVA corrected for multiple
comparisons with a Tukey post-hoc test).
3.4 Discussion
In this study, we evaluated whether cortical neurons transfected with select
GluN2A gain-of-function mutants would trigger excitotoxicity. We chose to evaluate
gain-of-function mutations located in the transmembrane domain (TMD) or linker
regions because these locations are correlated with the most severe outcomes for
epilepsy-aphasia spectrum (EAS) disorders (Strehlow et al., 2018). These severe
phenotypes include brain atrophy, continuous spike and wave during slow-wave sleep,
and an earlier onset of disease progression.
Since NMDA receptors harboring GluN2A gain-of-function mutations are more
readily activated, we presumed that expression of these subunits in neurons could
result in excitotoxicity due to amplified influx of Ca2+ by NMDA receptors. To measure
the extent of potential excitotoxicity, we quantified neurite blebbing, a cellular marker of
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excitotoxicity. We found that neurons transfected with GluN2A subunits with mutations
in the TMD or linker regions all caused cell blebbing (Figure 3.1B & C). However, while
the modest increase in cellular toxicity was relatively equivalent among mutant
transfected cells, only neurons expressing GluN2A-L812M subunits showed statistically
significant blebbing compared to GluN2A-WT controls. From these data we conclude
that there is no evidence for pronounced excitotoxicity resulting from expression of
severe GluN2A gain-of-function mutants in primary cortical cultures.
To further define whether the minimal cell blebbing was a result of overactive
NMDA receptors harboring GluN2A gain-of-function mutations, we assessed if blebbing
could be rescued by MPX-007, a GluN2A-selective negative allosteric modulator (NAM),
or memantine, a non-selective NMDA receptor allosteric antagonist. If blebbing was a
consequence of excitotoxicity from hyperactive NMDA receptors, then NMDA receptor
antagonists should ameliorate the resulting excitotoxicity.
We found that both 3 and 30 µM MPX-007 were able to significantly reduce
blebbing seen in neurons harboring GluN2A-P552R subunits, albeit these subunits did
not cause significant blebbing compared to GluN2A-WT transfections. We did not find a
significant reduction in bleb formation after treatment with NMDA receptor antagonists in
neurons transfected with other GluN2A gain-of-function mutations (i.e. GluN2A-N615K
and -L812M). Since transfections of GluN2A gain-of-function mutations do not cause
pronounced excitotoxicity, which is sensitive to NMDA receptor antagonist treatment,
we speculate that NMDA receptor-mediated excitotoxicity is not a major determinant of
the disease pathology caused by these de novo mutations in EAS disorders.
It is possible that these GluN2A subunits with gain-of-function mutations are not
successfully trafficked to the surface or properly localized at the cell surface. This could
explain why excitotoxicity does not result from expression of GluN2A gain-of-function
mutations. Future studies should be directed at quantifying both intracellular and cell
surface expression of these subunits. If subunits are not reaching the surface, it is
possible that the disease phenotype results from a lack of GluN2A subunit presence.
This deduction would fit into the observation that both GluN2A loss- and gain-of-function
mutations cause EAS. Alternatively, the detrimental effects of GluN2A gain-of-function
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mutations could be more pronounced in other cell types, like subpopulations of
inhibitory interneurons. In the case of interneurons, if mutations cause a loss-of-function
phenotype, say by deficient trafficking to the membrane, then the excitatory/inhibitory
balance would shift towards excitotoxicity. This could serve as a potential mechanism to
explain seizure activity seen in both GluN2A gain and loss-of-function mutations.
4.0 Quantification of excitotoxicity in CA1 pyramidal neurons expressing GluN2A gainof-function mutants
4.1 Introduction
Seizures result from the hypersynchronous discharge of a population of neurons,
a consequence of hyperexcitable neurons. Hyperexcitability can result from various
mechanisms including increased excitatory neurotransmission, decreased inhibitory
drive, changes in the extracellular ionic milieu (i.e. increases in external K +), and/or
alterations in ion channel function. All of these mechanisms act to shift the excitatory
and inhibitory balance to a more excitable state.

Gain-of-function mutations in GRIN2A can cause increases in NMDA receptor
agonist potency, increased channel open time and probability, and an increase in the
duration of channel closure, among other facets that promote hyperexcitability (Endele
et al., 2010; Yuan et al., 2014; Swanger et al., 2016; Chen et al., 2017; Ogden et al.,
2017; Xu et al., 2018). These states are thought to promote neuronal hyperexcitability
by increasing the likelihood of NMDA receptor activation, and for some GRIN2A
mutants, also increasing the duration of NMDA receptor channel opening. Since NMDA
receptors are permeable to mono- and divalent cations, increases in channel open
probability and duration can result in a substantial intracellular increase of positive ions
which can promote neuronal depolarization. As this permeation spreads throughout the
neuron, local depolarizations can summate and trigger an action potential. One can
imagine how this process could proceed in nearby excitatory neurons to disrupt the
excitatory/inhibitory balance, and lead to seizure activity.
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As epilepsy is a primary outcome of GRIN2A mutations, it seems probable that
GRIN2A gain-of-function mutations can lead to seizure disorders due to NMDA
receptor-mediated increases in hyperexcitability. However, GRIN2A loss-of-function
mutations also cause epilepsy-aphasia spectrum disorders (EAS) (Gao et al., 2017;
Strehlow et al., 2018). Recently, Salmi and colleagues (2019) generated GRIN2A
knock-out mice and characterized social deficits and EEG abnormalities during the first
two months of postnatal development. They found that, compared to wild-type
littermates, GRIN2A knock-out mice showed impaired verbal communication (measured
by frequency and type of ultrasonic vocalization) that peaked in severity between
postnatal day six and eight. Additionally, they identified increased spontaneous spikewave discharges during slow-wave sleep, a common theme in EAS disorders, which
disrupted sleep duration and quality (measured by the number of transitions between
wakefulness, slow-wave, and paradoxical sleep per hour) at one month of age. While
sleep quality recovered by two months of age, spike-wave discharges were present in
mice throughout the study (up to two months). Interestingly, GRIN2A-/+ heterozygotes
did not show any differences in behavior or EEG patterns from wild-type littermates.

These data indicate that the GRIN2A pathophysiology of EAS disorders is more
nuanced than anticipated. As both GluN2A loss and gain-of-function mutants result in
EAS disorders, it is unknown whether seizures are a direct result of excitotoxicity arising
from neurons expressing these mutations, or if seizures are largely the result of faulty
network refinement during development. Here we have sought to delineate this
relationship by assessing neuronal blebbing and firing in organotypic slices transfected
with wild type GluN2A, GluN2A-L812M, or GluN2A-P552R subunits. We found that cells
transfected with GluN2A-P552R subunits do not bleb more than neurons transfected
with GluN2A-WT subunits. In contrast, GluN2A -L812M transfected neurons showed
significant blebbing that could be rescued by treatment with memantine. Furthermore,
pyramidal neurons transfected with GluN2A-WT, -P552R, or -L812M subunits did not
exhibit different firing from un-transfected controls. These data indicate that
excitotoxicity is not the primary driver of EAS disease pathology.
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4.2 Methods
4.2.1 Mouse brain dissection, cutting, and plating
Postnatal day 7-8 (P7-8) C57BL/6 mice of either sex were anesthetized with
isoflurane and decapitated in accordance with the Institutional Care and Animal Use
Committee and Department of Laboratory Animal Resources at the University of
Montana. The brain was rapidly dissected and promptly emerged in ice-cold, sterilefiltered, low Na+ artificial cerebral spinal fluid, containing in mM: 1 CaCl2, 10 D-Glucose,
4 KCl, 5 MgCl2, 26 NaHCO3, 234 Sucrose and 0.1% volume/volume phenol red
solution. Prior to decapitation, the low Na+ artificial cerebral spinal fluid was bubbled
with carbogen (5% CO2 and 95% O2) for 20 minutes while submerged in ice.
The whole brain tissue was incubated in ice-cold low Na+ artificial cerebral spinal
fluid for five minutes before removal of hippocampi. Hippocampi were transferred to a
McIlwain Tissue Chopper® and slices were cut at 400µM. Slices were then moved into
ice-cold Slice Culture Media: 8.4g/L MEM Eagle Medium, 20% Horse serum, 1 mM
GlutaMAX, 1 mM CaCl2, 2 mM MgSO4, 1 mg/L Insulin (dissolved in 0.01 M HCl),
0.00125% weight/volume Ascorbic Acid solution, 13 mM D-Glucose, 5.2 mM NaHCO3,
and 30 mM HEPES (pH 7.27-7.28; 320 mmol/kg osmolarity). Slices containing clear
hippocampal microstructures were isolated in ice-cold slice culture media and
transferred to 6-well plates containing 1.2 mL/well equilibrated (i.e. incubated in 37 0C,
5%CO2 for two hours) slice culture media. A maximum of five slices were plated on cell
culture inserts (Millicell; Millipore Sigma). Complete media changes were done the first
day after plating and then every two to three days (for more detail refer to Opitz-Araya
and Barria 2011).
4.2.2 Preparation of gene gun bullets for biolistic transfection
DNA for calcium-calmodulin kinase II (CaMKII) driven green fluorescent protein
(GFP), wild type GluN2A, GluN2A-P552R, GluN2A-L812M was purified using
endotoxin-free maxi-prep kits (Qiagen®) with a final concentration of 1-1.5 mg/mL. Prior
to preparing gene gun bullets, ~30 inches of Tefzel tubbing (Bio-Rad) was dried with N2
gas (0.4 pressure) for a minimum of 20 minutes. DNA was combined in a 1:1 ratio of
GFP to GluN2A wild type, or mutant, for a final concentration of 50 µg. This DNA mix
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was then combined with ~17 mg gold and coated with 100µL 0.05M spermidine. DNA
was then precipitated with 100µM 1M CaCl2 and washed with 100% ethanol and finally
dissolved in polyvinylpyrrolidone-ethanol solution to aid in coating the plastic tubing. The
DNA-gold- polyvinylpyrrolidone-ethanol solution was then injected into the Tefzel tubing
and allowed to settle for five minutes. The solution was then aspirated off, and the
remaining DNA-gold mixture was dried with N2 gas (0.4 pressure) for 5 minutes. The
tubbing was then removed and cut into bullets for loading into the Helios® Gene Gun
(Bio-Rad).
4.2.3 Transfection of organotypic slices
Slices cultured in vitro for 10 days (DIV 10) were transfected with gene gun
bullets propelled by helium gas at 100 psi. Slices were either incubated in the presence
or absence of 50µM memantine beginning four to six hours following transfection. Slices
were then either fixed in 4% paraformaldehyde for image processing or prepared for
dual whole or lose-patch recordings three days after transfection.
4.2.4 Preparation of slides for microscopy
Paraformaldehyde was removed from 24-well plates containing hippocampal
slices and slices were washed three times with HBSS containing Ca2+ and Mg2+ (Life
Technologies). Slices were then permeabilized in 0.3% Triton X-100 (Sigma-Aldrich)
and subsequently labeled with Neurotrace (Life Technologies). After a 30-minute
incubation in Neurotrace, slices were washed three times with HBSS containing Ca 2+
and Mg2+ and mounted on slides with DAPI Vectaschield mounting medium (Vector
Laboratories) before being sealed with clear nail polish. Slides were stored in a 4 0C
refrigerator until processing.
4.2.5 Confocal imaging and analysis of organotypic slices
Hippocampal slices were imaged using a Zeiss® 880 confocal laser scanning
microscope (Zeiss LSM 880). Images were obtained at 20x magnification and z-stacks
were established to have 50% overlap between 0.88µM sections. Z-stacks were
analyzed by performing a maximum intensity projection (Fiji). The image was then
converted into a binary bit image by setting the threshold to 2x the background noise.
Neuronal blebbing was then quantified using the “analyze particles” feature in Fiji. Two
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measurements were taken using this plug-in feature, the first being the total cell area (0infitie µM; circularity 0-1), and the second quantifying neural cell blebbing (3-infitie µM;
circularity 0.35-1).
Percent blebbing was calculated as the ratio of the total blebbing area to the total
cell area. Only neurons showing at least three branch points were included for analysis.
Values were plotted using Prism8® (GraphPad) and data were analyzed using one-way
ANOVA with mutants compared to wild type, followed with a Tukey post-hoc test and
regarded as significant if p<0.05.
4.2.6 Dual patch recording and analysis of spike frequency
Transfected slices were moved to the recording chamber containing artificial
cerebrospinal fluid in mM: 125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4*H2O, 20 Dglucose, 2 CaCl2, and 1 MgCl2. Glycine, 3 µM, was added for both dual whole-cell and
loose-patch recordings, and 10 µM 2-chloroadenosine was added to the artificial
cerebral spinal fluid for dual whole-cell patch recordings. Solution was perfused at 2.5
mL/min and synaptic responses were evoked by a monopolar electrode placed to
stimulate Schaeffer collaterals.
For dual whole-cell patch recordings, the internal solution consisted of in mM:
120 Cs-MeSO3, 15 CsCl, 10 TEA-Cl, 10 HEPES, 8 NaCl, 4 Mg-ATP, 1 MgCl2, 5 QX314, 0.3 Na-GFP, and 0.3 EGTA. pH was adjusted by CsOH and the osmolality was
adjusted to 290 mOsm. Borosilicate glass electrodes were pulled from a P-1000
Micropipette puller (Sutter Instruments) with resistances of 3 – 5 MΩ. DNQX (10 µM)
GABAzine (10 µM), MPX-007 (3 and 30 µM), and APV (100 µM ) solutions were made
the day of recordings in fresh artificial cerebral spinal fluid.
For loose-patch recording, artificial cerebral spinal fluid was used to fill electrodes
with resistances of 2 – 4 MΩ. During the recording, membrane holding current, input
resistance, and pipette series resistance were monitored. Data were gathered through a
MultiClamp 700B amplifier (Axon Instruments) using pClamp10 (Molecular Devices),
filtered at 1 kHz, and digitized at 8 kHz. Data were analyzed using Axograph software
(axograph.com) and plotted using Prism8 (GraphPad). Statistical significance was
assessed by using two-tailed Wilcoxon signed rank tests.
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4.3 Results
We began our investigation into neuronal excitotoxicity triggered by GluN2A
gain-of-function containing NMDA receptors by first assessing cell toxicity in organotypic
slice culture by measuring blebbing as described in Aim 2. Briefly, we were able to
direct expression of subunits in excitatory cells by use of plasmids containing green
fluorescent protein (GFP) or GluN2A subunits, both driven by a calcium-calmodulin
kinase (CaMKII) promoter. As CaMKII is only expressed in excitatory neurons (Jones et
al., 1994; Wang et al., 2014), we were able to ask whether expression of mutated
GluN2A subunits mediate excitotoxicity in cultured CA1 pyramidal neurons from
organotypic hippocampal slice. Mature slices, equivalent to postnatal 20-21 (P20-21)
day old mice, were dissected at P7-8, transfected at day in vitro 10 (DIV 10), and fixed
for imaging, or used in recordings, on DIV 13 (Figure 4.1A).
Organotypic slices transfected with GFP alone and GFP with GluN2A-P552R
subunits showed similar blebbing in the absence (GFP = 12.8 ± 3.5%; GFP + GluN2AP552R = 10.5 ± 1.6%) and presence of 50 µM memantine (GFP = 8.59 ± 2.4%; GFP +
GluN2A-P552R = 10.3 ± 1.3%). These results suggest that in organotypic CA1
pyramidal cells, the presence of GluN2A-P552R subunits is not toxic compared to
control GFP transfected cells. Similarly, GFP and GluN2A-WT transfected cells treated
with memantine showed similar cell blebbing (GFP + GluN2A-WT = 10.9 ± 0.3%),
though more data need to be collected to elucidate a difference between cells
transfected with GFP and GFP + GluN2A-WT in the absence of memantine.
Unlike cells transfected with GluN2A-P552R, GluN2A-L812M transfected cells
showed significant blebbing (Figure 4.1B-D) (GFP + GluN2A-L812M 32.3 ± 12%; twoway ANOVA with Tukey post-hoc test, p < 0.05). Blebbing in cells transfected with
GluN2A-L812M was rescued with 50 µM memantine incubation (GFP + GluN2A-L812M
7.90 ± 2.1%), suggesting that toxicity is due to aberrant NMDA receptor signaling.
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Seeing that expression of GluN2A gain-of-function mutants do not consistently
cause blebbing (i.e. cytotoxicity), we sought to characterize a possible link to neuronal
hyperexcitability by assessing properties of synaptic transmission. We hypothesized
that hyperexcitability could manifest as increased action potential firing in neurons with
expression of GluN2A gain-of-function mutants. To isolate signaling differences without
perturbing the intrinsic properties of neurons, we evaluated neuronal firing frequency by
loose-patch recordings. Loose-patch recordings entail electrophysiological assessment
of the ionic environment just outside of the cell membrane, therefore leaving the internal
cellular composition intact.

Figure 4.1: Characterization of blebbing in aged organotypic hippocampal
slices. A) Timeline of organotypic slice preparation. Slices are aged to reflect P2021 day old mice. B) Representative image of CA1 pyramidal cells transfected with
GFP and GluN2A-L812M in the absence and C) presence of 50 µM memantine. D)
Summary plot of neurite blebbing in CA1 pyramidal cells of transected organotypic
slices. Data are mean ± SEM from 3-13 neurons. *Indicates significantly different
(p<0.05 two-way ANOVA corrected for multiple comparisons with a Tukey post-hoc
test).
Due to intrinsic cell-by-cell variability among cultured slices, we assessed
simultaneous dual-patch recordings to accurately tease apart differences in signaling in
a neuron transfected with GluN2A gain-of-function mutants compared to a neighboring
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un-transfected control neuron (Figure 4.2A). We found that GluN2A-WT or mutant
transfected CA1 pyramidal cells did not show significantly different signaling properties
compared to un-transfected controls (Figure 4.2 B-E) (p > 0.05 Wilcoxon paired signedrank test). This suggests that expression of GluN2A-WT, GluN2A-L812M, or GluN2AP552R do not cause hyperexcitability in CA1 pyramidal cells as measured by action
potential firing in organotypic slices.
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Figure 4.1: Neuronal firing rates in transfected organotypic slice. A)
Representative image illustrating electrode placement in the CA1 region of the
hippocampus. B) GluN2A-WT, C) GluN2A-L812M, D) GluN2A-P552R firing
frequency plotted against un-transfected cell firing frequency. E) Summary plot
illustrating that GluN2A gain-of-function mutations had no significant effect on firing
frequency compared to un-transfected controls, summary plot. Data are mean ± SEM
from 3-8 slices.
We speculated that transfection of GFP or GluN2A subunits may cause synaptic
alterations that could perturb accurate delineation of signaling differences between
transfected and un-transfected cells. To evaluate this possibility, we measured evoked
excitatory post-synaptic currents (EPSCs) in dual whole-cell patch recordings
comparing un-transfected with GFP, or GFP + GluN2A transfected cells (Figure 4.3).
With our preliminary data, we see that transfection does not alter synaptic signaling
properties (Figure 4.3).

Figure 4.3: Evoked synaptic transmission properties in transfected organotypic
slice. A) Schematic illustrating stimulating and dual whole-cell patch clamp electrode
placement. Adapted from Chen et al., 2012. B & D) AMPA receptor elicited currents
measured at -60mV and NMDA receptor responses measured at +40mV (C & E) in
baseline (black), 3 µM MPX-007 (green), 30 µM MPX-007 (red), and 100 µM APV
(blue). Un-transfected cells (UT) are shown on top and simultaneous dual whole-cell
patch of GFP (B-C) and GluN2A-WT (D-E) transfected slices are represented in the
bottom panels.
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The preliminary data presented in this aim provide no clear evidence that
GluN2A gain-of-function mutants mediate neuronal excitotoxicity. While transfection of
GluN2A-L812M subunits caused neuronal blebbing, which could be rescued with
memantine, we did not see a difference in neuronal firing, a canonical measure of
excitability. Furthermore, these was no indication that expression of GluN2A-P552R
subunits cause cell blebbing, a hallmark of impeding cell death, or abnormal signaling in
transfected CA1 pyramidal cells in organotypic slices. We also did not observe
interferences in synaptic signaling, assessed by the NMDA receptor mediated EPSC
time course, upon transfection (Figure 4.3). These preliminary data suggest that
excitotoxicity is not the sole determinant of aberrant neuronal signaling properties
caused by NMDA receptors harboring GluN2A gain-of-function mutations.
4.4 Discussion
Here we sought to determine whether select GluN2A gain-of-function mutations
mediate excitotoxicity or hyperexcitability in CA1 pyramidal cells in mature organotypic
slices. NMDA receptors harboring GluN2A gain-of-function mutations are more easily
activated, for example due to increased agonist potencies or relief of tonic endogenous
Mg2+ inhibition. Therefore, it is conceivable that deleterious outcomes seen in children
with epilepsy-aphasia spectrum (EAS) disorders result from NMDA receptor-induced
excitotoxicity. In this study, we assessed excitotoxicity by evaluating neural blebbing
and measuring firing frequency in aged organotypic hippocampal slices.
The hippocampus is an important region for establishing declarative memories,
which are memories that form based on associative sensory experience (Review
Dumas, 2005). Children with (EAS) disorders often present with difficulties in speech
output and understanding, a process involving declarative memory processing. With this
in mind, we assessed excitotoxicity in the hippocampus due to its involvement in EAS
disorders and declarative memory formation.
Extent of excitotoxicity was assessed by quantifying neurite blebbing, a
consequence of excitotoxicity, and hyperexcitability was assessed by measuring
neuronal firing frequency in mature organotypic slices. The slices were effectively aged
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at 20-21 days because they were isolated from postnatal day 7-8 (P 7-8) mice and
grown in culture for a total of 13 days. By the third week after birth, the developmental
switch from GluN1/GluN2B diheteromer NMDA receptors to NMDA receptors that also
contain GluN2A subunits (e.g. GluN1/GluN2A/GluN2B triheteromers) is well underway
in rodents (Monyer at al., 1994; Sheng et al., 1994). It is during this developmental
switch in humans that the GluN2A-mediated severe EAS begins to manifest in children.
We found that transfection of GluN2A-L812M, but not GluN2A-WT or GluN2AP552R subunits caused neural blebbing, a known consequence of excitotoxicity (Figure
4.1). Furthermore, blebbing seen in neurons expressing GluN2A-L812M could be
rescued with incubation of 50 µM memantine, a non-selective NMDA receptor
antagonist. These data indicate that NMDA receptors harboring GluN2A-L812M
subunits mediate excitotoxicity in CA1 pyramidal neurons.
Memantine has shown clinical efficacy in treatment of a patient harboring the
GluN2A-L812M mutation (Pierson et al., 2014). This patient developed severe
continuous spike-wave during slow wave sleep seizure activity with multiple seizures
daily. The patient exhibited refractory epilepsy and had been administered lacosamide,
rufinamide, and valproic acid without seizure resolution (mg/kg per day: lacosamide
11.25; rufinamide 45; valproic acid 25). Upon administration of memantine (~0.5mg/kg
daily), seizure frequency reduced to 3 per week and myoclonic jerks dissipated
completely. No cognitive differences were apparent after memantine treatment. The
amelioration in symptom progression in this patient with the GluN2A-L812M mutation is
consistent with our data showing that GluN2A-L812M subunit-induced hippocampal
excitotoxicity could be rescued with memantine.
Our finding that GluN2A-L812M, but not GluN2A-P552R expression, caused
significant blebbing in hippocampal pyramidal cells suggest that excitotoxicity is not the
sole determinant of the symptoms observed in the EAS patients. It is possible that
different mutations mediate excitotoxicity to different cell types (i.e. excitatory vs
inhibitory neurons) and future experiments should assess excitotoxicity in distinct cell
types. Thus, we deduce that excitotoxicity resulting from NMDA receptors harboring
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GluN2A gain-of-function mutations does not fully describe the pathologies associated
with EAS.
Another potential outcome of the GluN2A gain-of-function mutations could be
hyperexcitability, which could lead to increased seizure activity. This possibility was
evaluated by assessing aberrant increases in firing frequency. Neuronal
hyperexcitability in CA1 pyramidal cells may be accompanied by excitotoxicity, but the
two potential consequences of GluN2A gain-of-function mutations are not necessarily
always directly linked. Since approximately 90% of patients with GRIN2A mutations
present with seizure disorders (XiangWei et al., 2018), we sought to characterize
abnormal firing frequency in organotypic slices transfected with GluN2A-L812M or P552R subunits compared to GluN2A-WT controls. Interestingly, we found no
significant difference between GluN2A gain-of-function in transfected slices compared
to GluN2A-WT transfected slices (Figure 4.2). This further suggest that neither
excitotoxicity nor hyperexcitability in pyramidal cells are the predominant mechanisms of
disease pathology for patients harboring GluN2A gain-of-function mutations.
However, it is possible that biolistic transfection alters synaptic properties. Under
this assumption, we would not be able to delineate a difference between GluN2A gainof-function and GluN2A-WT transfections due to general synaptic dysfunction resulting
from transfection. In order to assess this possibility, we evaluated evoked excitatory
post-synaptic currents (EPSCs) in dual whole-cell patch recordings. Our preliminary
data indicate that synaptic properties are unaltered in both GFP and GFP + GluN2A-WT
transfected cells compared to un-transfected cells (Figure 4.3). We assessed AMPA
receptor activation at negative holding potentials and NMDA receptor activation at
positive potentials and saw no difference in simultaneous recordings of un-transfected
cells. We were also able to measure MPX-007 mediated inhibition, which was fully
recapitulated in transfected and un-transfected cells, indicating the presence of synaptic
GluN2A-containing NMDA receptors (Figure 4.3).
Here, we conclude that in our experimental conditions there is no evidence for
GluN2A gain-of-function induced excitotoxicity or hyperexcitability in CA1 pyramidal
cells. While GluN2A-L812M transfected CA1 pyramidal neurons showed cell blebbing
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that was reduced with memantine, dual-patch recordings did not demonstrate
excitotoxic neuronal signaling. Furthermore, cells transfected with GluN2A-P552R
subunits did not show differences in neurotoxicity or signaling. If excitotoxicity or
hyperexcitability are the primary drivers of disease pathology, then we would expect to
see some indications of these phenotypes following expression of the severe GluN2A
gain-of-function mutants in CA1 pyramidal cells. We have not consistently seen this,
indicating that the disease pathology is more nuanced. Interestingly, our data are in
agreement with the finding that GluN2A loss-of-function mutants also cause EAS
disorders, including seizures, which cannot be canonically explained by straightforward
excitotoxicity or hyperexcitability of pyramidal cells.
Future experiments should quantify the extent and localization of GluN2A gainof-function subunits in different cell types to determine if pathology is specific to
particular cell types, or if these subunits are trafficked to the cell surface or synapse.
Additionally, since seizures only occur during slow-wave sleep, it would be prudent to
assess the dependence of seizure activity in relation to slow-wave oscillations.
Furthermore, as kids with EAS are unable to solidify verbal learning and memory, it
would be interesting to quantify possible differences in long-term potentiation or
depression and episodic memory retention. The contribution of GluN2A gain-of-function
mutants in these physiological processes could elucidate foundations for cognitive
impairment seen in kids with severe EAS.
5.0 General Discussion
In this body of work, we have characterized GluN2A-selective negative allosteric
modulation of NMDA receptors harboring GluN2A gain-of-function mutations and
assessed GluN2A gain-of-function mediated links to excitotoxicity and hyperexcitability
in excitatory neurons. We assessed GluN2A gain-of-function mutations identified in
children with epilepsy-aphasia spectrum (EAS) disorders, of varying severity. We
selected six mutations with disparate domain localization in NMDA receptors, including
mutations in the agonist binding domain (ABD), transmembrane domain (TMD), and
linker regions between the ABD and TMD (Figure 2.2).
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Out of the six representative GluN2A gain-of-function mutants, all but one
showed increases in both glycine and glutamate potencies (Figure 2.2). The GluN2AN615K mutant is insensitive to tonic inhibition by endogenous Mg2+, but does not alter
agonist or co-agonist potencies, or sensitivities to other endogenous modulators Endele
et al., 2010). Therefore, this mutant served as a positive control in our experiments as it
behaves like GluN2A-wild type (GluN2A-WT) containing NMDA receptors in terms of
agonist potencies and deactivation time course.
Since NAM mediated inhibition acts to destabilize glycine binding (Figure 2.5), it
was unknown whether NAMs could overcome increases in glycine potency seen in
NMDA receptors with GluN2A gain-of-function mutations. Despite upwards of 10-fold
increases in glycine potency, NAMs were still able to inhibit NMDA receptors containing
GluN2A gain-of-function mutations (Figure 2.3). Decreased sensitivity to NAM inhibition
was highly correlated to increases in glycine potency for all mutants except for NMDA
receptors harboring GluN2A-P552R mutations (Figure 2.4).
To investigate the discrepancy in GluN2A-P552R mutant sensitivity to NAMmediated inhibition, we calculated the NAM binding affinity (KB) and allosteric constant
(α) for a subset of the GluN2A gain-of-function mutations, including GluN2A-P552R. We
evaluated glycine concentration-response curves in the increasing presence of NAM
(TCN-201) and performed Schild analysis to determine potential differences in KB or α.
Again, GluN2A-N615K served as our positive control and showed no alterations in KB or
α compared to GluN2A-WT values. Similarly, as expected GluN2A-L812M containing
NMDA receptors showed no significant differences in KB or α compared to GluN2A-WT
values. Interestingly, GluN2A-P552R containing receptors showed a 10-fold decrease in
KB, indicating that this mutation changes the dimer interface where NAMs bind (Figure
2.6).
We next sought to determine whether NAMs were effective at inhibiting NMDA
receptors containing GluN2A gain-of-function mutations under synaptic-like events.
Glutamate is released from presynaptic sites and persists in the synaptic cleft for a few
milliseconds (~3-5 ms; Clements et al., 1992) before being removed by glutamate
transporters (Danbolt, 2001). We mimicked this physiological glutamate time course
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with HEK293 cells transfected with GluN1A and GluN2A gain-of-function mutants to
determine NAM mediated inhibition under non-steady state kinetics.
We assessed extent of NAM inhibition in both low and mid-range physiological
glycine levels (i.e. 3 and 10 µM glycine). Surprisingly, despite increases in glycine
potency measured during steady-state conditions in Xenopus oocytes, non-equilibrium
responses did not reflect a significant increase in glycine potency (Figure 2.8), except
for NMDA receptors containing GluN2A-P552R mutations. This disparity in equilibrium
and non-equilibrium potencies could reflect the absence of NMDA receptor
desensitization in our recapitulated synaptic-like time course.
During NMDA receptor desensitization, the channel closes but agonists remain
bound. In this state, increases in agonist potency could result from increased agonist
occupancy when the channel re-enters states that allow for channel opening (Figure
2.9). However, during synaptic-like activation in HEK293T cells, NMDA receptor
desensitization is minimized and thus the state-mediated effects on agonist potency are
virtually eliminated. This phenomenon could reflect the apparent decreases in agonist
potency in non-equilibrium vs steady-state responses. Along these same lines, we
found that NAMs were more effective at inhibiting NMDA receptors containing GluN2A
gain-of-function mutations under synaptic-like activation (Figure 2.8).
Seeing as some NMDA receptors harboring GluN2A gain-of-function mutations
show increased agonist potencies (Figure 2.2) and slowed deactivation kinetics (Figure
2.7), we postulated that excitatory neurons transfected with these mutants would show
signs of excitotoxicity. We first evaluated excitotoxicity in mature cortical neurons
transfected with green fluorescent protein (GFP) and either GluN2A-WT or GluN2A
gain-of-function mutants driven by a calcium-calmodulin kinase (CaMKII) promoter.
CaMKII is selectively expressed in excitatory neurons, which allowed us to target our
excitotoxicity hypothesis directly to excitatory neurons. Furthermore, we chose to assay
GluN2A subunits with mutations in the TMD or linker regions because mutations located
in these domains are associated with the more severe phenotypes documented in EAS,
including both grey and white matter atrophy (Strehlow et al., 2018).
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We found that neurons transfected with GluN2A-P552R, GluN2A-N615K, and
GluN2A-L812M subunits did not show pronounced neurite blebbing, a symptom of
excitotoxicity, as compared to GluN2A-WT transfected controls (Figure 3.1). While
GluN2A-L812M transfections showed statistically significant blebbing compared to
GuN2A-WT transfections, the amount of blebbing was minimal (2.8%). This was
surprising seeing as these same mutations are associated with epileptic
encephalopathy in humans (Endele et al., 2010; Strehlow et al., 2018; Pierson et al.,
2014; Yuan et al., 2014; Ogden et al., 2017). Together, these data indicate that EAS
resulting from GluN2A gain-of-function mutations is more complicated than simply
arising from excitotoxicity.
To rule out other contributions of GluN2A gain-of-function mutations to
excitotoxicity, we also assessed neural blebbing in CA1 hippocampal cells of
organotypic slices (Figure 4.1). The hippocampus is involved in establishing declarative
memories, which are learned, associative memories (Review – Dumas, 2005). Verbal
associative memory formation is drastically impaired in children with EAS and therefore
we speculated that hippocampal cells may be more sensitive to NMDA receptors
harboring GluN2A gain-of-function mutations.
Similar to our results seen in cortical neurons, transfection of mature
hippocampal cells resulted in significant blebbing from GluN2A-L812M transfections, but
not from GluN2A-P552R expression. Furthermore, the blebbing seen in neurons
transfected with GluN2A-L812M could be rescued by incubation with memantine, a nonselective NMDA receptor antagonist. Benefits of memantine exposure have been
documented in a patient with the GluN2A-L812M mutation, which correlates well with
our neuron data (Pierson et al., 20414). Memantine treatment was able to drastically
reduce seizure frequency from multiple times a day to approximately 3 per week in a
patient with the GluN2A-L812M mutation.
However, not all GluN2A gain-of-function mutations caused excitotoxicity in cell
culture (Figures 3.1 and 4.1), despite the severity of disease associated with these
mutations. This indicates that disease severity is not exclusively based upon
excitotoxicity caused by these mutations. Alternatively, the excitotoxicity could be more
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apparent in other cell types, such as inhibitory interneurons. If interneurons are
selectively eliminated to excitotoxicity, disparities in the excitatory/inhibitory balance,
along with network oscillations could contribute to seizure propagation. Future studies
should investigate GluN2A gain-of-function mutant effects in interneurons.
It is possible that these mutated GluN2A subunits are not efficiently trafficked to
the surface and/or the synapse. Indeed, some mutants have documented decreases in
cell surface expression, which essentially results in a loss-of-function phenotype (Ogden
et al., 2017). Interestingly, both GluN2A gain and loss-of-function mutations are
associated with EAS disease etiology. Future studies should address this possibility and
quantify cell surface expression for GluN2A gain- and loss-of-function mutants.
While we did not see excitotoxicity evaluated by neural blebbing, we postulated
that hyperexcitability could be apparent in neuronal signaling properties. Seeing as
approximately 90% of individuals with mutations in GluN2A present with epilepsy
(XiangWei et al., 2018), we hypothesized that neurons transfected with GluN2A gain-offunction mutations would show aberrant firing due to hyperexcitable neurons.
To determine differences in neuronal signaling, we transfected mature
organotypic slices with GFP and either GluN2A-WT, GluN2A-P552R, or GluN2A-L812M
subunits. We performed dual loose-patch recordings as to avoid disrupting internal
properties of the neurons and to control for inherent variability in cell signaling
properties identified in slice culture. We found that neurons transfected with GluN2A-WT
or gain-of-function mutations did not show significantly different signaling properties
from un-transfected cells recorded in the same slice.
It is possible that biolistic transfection of slices causes detriments in synaptic
signaling, which would occlude accurate delineation of signaling properties between
transfected conditions. Therefore, we also assessed conservation of excitatory postsynaptic currents (EPSCs) in dual-whole cell patch clamp experiments (Figure 4.3). We
did not see an effect of transfection when comparing neurons transfected with either
GFP or GFP with GluN2A-WT subunits with un-transfected controls in the same slice.
This indicates that synaptic properties are conserved in biolistic-transfected slices.
Albeit, future experiments are required to determine if GluN2A subunits with gain-of71

function mutations are trafficked to the synapse and affect NMDA receptor-mediated
EPSCs by slowing the decay time course.
Together, these data provide no clear evidence that GluN2A gain-of-function
mutations mediate pronounced excitotoxicity measured by both neural blebbing or
mediate hyperexcitability in excitatory neurons. While unexpected, these data are better
understood in light of GluN2A loss-of-function mutations that also cause EAS disorders
with similar seizure activity as compared to GluN2A gain-of-function mutations.
Therefore, the etiology of NMDA receptor dysfunction resulting from mutated GluN2A
subunits is more nuanced than simply propagating due to unrequited excitotoxicity and
hyperexcitability of pyramidal cells. A more subtle model of poor signal integration may
serve as a better foundation to describe the etiology of EAS disorders involving
mutations in GRIN2A. Since NMDA receptors coordinate neuronal firing with sensory
experience, any disruption in this system could manifest as deficits in declarative
memory.
Future studies should narrow down the plethora of avenues that could cause
aberrant wiring due to NMDA receptors containing gain- or loss-of-function GluN2A
subunits. Interneurons, rather than excitatory neurons, could be the primary targets of
GluN2A-mediated malfunction. In this case, interneurons harboring essentially loss-offunction GluN2A subunits could tilt the excitatory/inhibitory balance towards
excitotoxicity due to a loss in inhibitory tone. Or rather, it is possible that these subunits
are not efficiently trafficked to the membrane in all cell-types, and therefore also present
as loss-of-function mutants. Future studies should focus on teasing apart these
attributes so that we can gain a better understanding of GRIN2A mutation involvement
in EAS disorder pathology.

72

6.0 Works Cited
Aarts, M; Y. Liu, L. Liu, S. Besshoh, M. Arundine, J.W. Gurd, Y.T. Wang, M.W. Salter,
M. TymianskiTreatment of ischemic brain damage by perturbing NMDA receptorPSD-95 protein interactions Science, 298 (5594) (2002), pp. 846-850 View Record in
ScopusGoogle Scholar
Addis, L., Virdee, J. K., Vidler, L. R., Collier, D. A., Pal, D. K., & Ursu, D. (2017).
Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and
agonist potency-molecular profiling and functional rescue. Scientific Reports, 7(1), 1–
14. https://doi.org/10.1038/s41598-017-00115-w\
Akazawa C., Shigemoto R., Bessho Y., Nakanishi S., and Mizuno N. (1994).
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the
cerebellum of developing and adult rats. J. Comp. Neurol. 347:150–160.
10.1002/cne.903470112 [PubMed] [CrossRef] [Google Scholar]
Al-Hallaq R.A., Conrads T.P., Veenstra T.D., and Wenthold R.J. 2007. NMDA diheteromeric receptor populations and associated proteins in rat hippocampus. J.
Neurosci. 27:8334–8343. 10.1523/JNEUROSCI.2155-07.2007 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Aman T.K., Maki B.A., Ruffino T.J., Kasperek E.M., and Popescu G.K. 2014.
Separate intramolecular targets for protein kinase A control N-methyl-D-aspartate
receptor gating and Ca2+ permeability. J. Biol. Chem. 289:18805–18817.
10.1074/jbc.M113.537282 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Anderson JD, Poulzet B. Spatial memory deficits induced by perinatal treatment of
rats with PCP and reversal effect of D-serine. Neuropsychopharmacology (2004)
29:1080–90. 10.1038/sj.npp.1300394 [PubMed] [CrossRef] [Google Scholar]
Andreescu, C., F. Prestori, F. Brandalise, A. D’Errico, M.T. De Jeu, P. Rossi, L. Botta,
G. Kohr, P. Perin, E. D’Angelo, C.I. De Zeeuw NR2A subunit of the N-methyl Daspartate receptors are required for potentiation at the mossy fiber to granule cell
synapse and vestibulo-cerebellar motor learning Neuroscience, 176 (2011), pp. 274283
Arunlakshana O, Schild HO. (1959) Some quantitative uses of drug antagonists. Br
Pharmacol Chemother 14:48–58 [PMC free article] [PubMed] [Google Scholar]
Bahn S., Volk B., Wisden W. (1994). Kainate receptor gene expression in the
developing rat brain. J. Neurosci. 14 5525–5547. 10.1523/JNEUROSCI.14-0905525.1994 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73

Barria A., Malinow R. (2002). Subunit-specific NMDA receptor trafficking to synapses.
Neuron 35 345–353. 10.1016/S0896-6273(02)00776-6 [PubMed] [CrossRef] [Google
Scholar]USA. 95:15730–15734. 10.1073/pnas.95.26.15730 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., … Nakazawa, K.
(2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers
schizophrenia-like phenotypes. Nature neuroscience, 13(1), 76–83.
doi:10.1038/nn.2447
Benveniste M., and Mayer M.L. 1991. Kinetic analysis of antagonist action at Nmethyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine.
Biophys. J. 59:560–573. 10.1016/S0006-3495(91)82272-X [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Berger A.J., Dieudonné S., and Ascher P. 1998. Glycine uptake governs glycine site
occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80:3336–
3340. 10.1152/jn.1998.80.6.3336 [PubMed] [CrossRef] [Google Scholar]
Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. 1998. Modulation of Nmethyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci.
Billups D., and Attwell D. 2003. Active release of glycine or D-serine saturates the
glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse.
Eur. J. Neurosci. 18:2975–2980. 10.1111/j.1460-9568.2003.02996.x [PubMed]
[CrossRef] [Google Scholar]
Bordji K., Becerril-Ortega J., Nicole O., Buisson A. (2010). Activation of extrasynaptic,
but not synaptic, NMDA receptors modifies amyloid precursor protein expression
pattern and increases amyloid-ß production. J Neurosci, 30(47), 15927–15942.
doi:10.1523/JNEUROSCI.3021-10.2010 [PMC free article] [PubMed] [Google
Scholar]
Borschel W.F., Cummings K.A., Tindell L.K., and Popescu G.K. 2015. Kinetic
contributions to gating by interactions unique to N-methyl-D-aspartate (NMDA)
receptors. J. Biol. Chem. 290:26846–26855. 10.1074/jbc.M115.678656 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Bourne H.R., and Nicoll R. 1993. Molecular machines integrate coincident synaptic
signals. Cell. 72(Suppl):65–75. 10.1016/S0092-8674(05)80029-7 [PubMed]
[CrossRef] [Google Scholar]
Bradley WG, Daroff RB, Fenichel JM, Jahrovic J. Neurology of clinical practice. 5th
Ed. 2009. pp. 1953–1990. [Google Scholar]

74

Brandt C, Potschka H, Löscher W, Ebert U. N-methyl-D-aspartate receptor blockade
after status epilepticus protects against limbic brain damage but not against epilepsy
in the kainate model of temporal lobe epilepsy. Neuroscience. (2003) 118:727–40.
10.1016/S0306-4522(03)00027-7 [PubMed] [CrossRef] [Google Scholar]
Burnashev N., Schoepfer R., Monyer H., Ruppersberg J.P., Günther W., Seeburg
P.H., and Sakmann B. 1992. Control by asparagine residues of calcium permeability
and magnesium blockade in the NMDA receptor. Science. 257:1415–1419.
10.1126/science.1382314 [PubMed] [CrossRef] [Google Scholar]
Burnashev N., Zhou Z., Neher E., and Sakmann B. 1995. Fractional calcium currents
through recombinant GluR channels of the NMDA, AMPA and kainate receptor
subtypes. J. Physiol. 485:403–418. 10.1113/jphysiol.1995.sp020738 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Carvill, G. L., Regan, B. M., Yendle, S. C., O’Roak, B. J., Lozovaya, N., Bruneau, N.,
… Mefford, H. C. (2013). GRIN2A mutations cause epilepsy-aphasia spectrum
disorders. Nature Genetics, 45(9), 1073–1076. https://doi.org/10.1038/ng.272
Chazot P.L., and Stephenson F.A. 1997. Molecular dissection of native mammalian
forebrain NMDA receptors containing the NR1 C2 exon: direct demonstration of
NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same
complex. J. Neurochem. 69:2138–2144. 10.1046/j.1471-4159.1997.69052138.x
[PubMed] [CrossRef] [Google Scholar]
Chen H.S., and Lipton S.A. 2006. The chemical biology of clinically tolerated NMDA
receptor antagonists. J. Neurochem. 97:1611–1626. 10.1111/j.14714159.2006.03991.x [PubMed] [CrossRef] [Google Scholar]
Chen N., Moshaver A., and Raymond L.A. 1997. Differential sensitivity of
recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol.
Pharmacol. 51:1015–1023. 10.1124/mol.51.6.1015 [PubMed] [CrossRef] [Google
Scholar]
Chen P.E., Geballe M.T., Katz E., Erreger K., Livesey M.R., O’Toole K.K., Le P., Lee
C.J., Snyder J.P., Traynelis S.F., and Wyllie D.J. 2008. Modulation of glycine potency
in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits
expressed in Xenopus laevis oocytes. J. Physiol. 586:227–245.
10.1113/jphysiol.2007.143172 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Chen W., Tankovic A., Burger P.B., Kusumoto H., Traynelis S.F., and Yuan H. 2017.
Functional Evaluation of a De Novo GRIN2A Mutation Identified in a Patient with
Profound Global Developmental Delay and Refractory Epilepsy. Mol. Pharmacol.
91:317–330. 10.1124/mol.116.106781 [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
75

Chen, M; R. Bullock, D.I. Graham, J.D. Miller, J. McCullochIschemic neuronal
damage after acute subdural hematoma in the rat: effects of pretreatment with a
glutamate antagonist J. Neurosurg., 74 (6) (1991), pp. 944-950 CrossRefView
Record in ScopusGoogle Scholar
Chen, M; T.J. Lu, X.J. Chen, Y. Zhou, Q. Chen, X.Y. Feng, L. Xu, W.H. Duan, Z.Q.
XiongDifferential roles of NMDA receptor subtypes in ischemic neuronal cell death
and ischemic tolerance Stroke, 39 (11) (2008), pp. 3042-3048 View Record in
ScopusGoogle Scholar
Chen BS, Gray JA, Sanz-Clemente A, Wei Z, Thomas EV, Nicoll RA, and Roche KW
(2012). SAP102 mediates synaptic clearance of NMDA receptors. Cell Rep. 2, 1120–
1128. [PMC free article] [PubMed] [Google Scholar]
Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing.
Pharmacol Rev 2002;54:323–74. [PubMed] [Google Scholar]
Cioffi, C. (2018) Glycine transporter-1 inhibitors: a patent review (2011-2016) Expert
Opin Ther Pat. 2018 Mar;28(3):197-210. doi: 10.1080/13543776.2018.1429408.
Citri A., and Malenka R.C. 2008. Synaptic plasticity: multiple forms, functions, and
mechanisms. Neuropsychopharmacology. 33:18–41. 10.1038/sj.npp.1301559
[PubMed] [CrossRef] [Google Scholar]
Clapham DE. Calcium signaling. Cell. (2007) 131:1047–58.
10.1016/j.cell.2007.11.028 [PubMed] [CrossRef] [Google Scholar]
Clements J.D., and Westbrook G.L. 1991. Activation kinetics reveal the number of
glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron.
7:605–613. 10.1016/0896-6273(91)90373-8 [PubMed] [CrossRef] [Google Scholar]
Clements J.D., and Westbrook G.L. 1994. Kinetics of AP5 dissociation from NMDA
receptors: evidence for two identical cooperative binding sites. J. Neurophysiol.
71:2566–2569. 10.1152/jn.1994.71.6.2566 [PubMed] [CrossRef] [Google Scholar]
Clements J.D., Lester R.A., Tong G., Jahr C.E., and Westbrook G.L. 1992. The time
course of glutamate in the synaptic cleft. Science. 258:1498–1501.
10.1126/science.1359647 [PubMed] [CrossRef] [Google Scholar]
Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic
transmission in the Schaffer collateral-commissural pathway of the rat hippocampus.
J Physiol. 1983;334:33–46. [PMC free article] [PubMed] [Google Scholar]
Costa A. C. Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.
Nat Rev Neurol 8, 182–184, doi: 10.1038/nrneurol.2012.40 (2012). [PubMed]
[CrossRef] [Google Scholar]

76

Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol
Neurobiol (2006) 26(4–6):365–84. 10.1007/s10571-006-9062-8 [PubMed] [CrossRef]
[Google Scholar]
Danbolt N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65 1–105. [PubMed]
[Google Scholar]
de Ligt J., Willemsen M. H., van Bon B. W. M., Kleefstra T., Yntema H. G., Kroes T.,
et al. (2012). Diagnostic exome sequencing in persons with severe intellectual
disability. N. Engl. J. Med. 367, 1921–1929. 10.1056/NEJMoa1206524 [PubMed]
[CrossRef] [Google Scholar]
Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine,
are we there yet? CNS Neurosci Ther. 2013;19:411–427. [PMC free article] [PubMed]
[Google Scholar]
Dumas TC. Developmental regulation of cognitive abilities: modified composition of a
molecular switch turns on associative learning. Prog Neurobiol. 2005;76:189–211.
doi: 10.1016/j.pneurobio.2005.08.002. [PubMed] [CrossRef] [Google Scholar]
Dunlop D. S., Neidle A. (2005). Regulation of serine racemase activity by amino
acids. Brain Res. Mol. Brain Res. 133, 208–214. 10.1016/j.molbrainres.2004.10.027
[PubMed] [CrossRef] [Google Scholar]
Ehlers M.D., Fung E.T., O’Brien R.J., and Huganir R.L. 1998. Splice variant-specific
interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments.
J. Neurosci. 18:720–730. 10.1523/JNEUROSCI.18-02-00720.1998 [PubMed]
[CrossRef] [Google Scholar]
Ehlers M.D., Zhang S., Bernhadt J.P., and Huganir R.L. 1996. Inactivation of NMDA
receptors by direct interaction of calmodulin with the NR1 subunit. Cell. 84:745–755.
10.1016/S0092-8674(00)81052-1 [PubMed] [CrossRef] [Google Scholar]
Endele, S., Rosenberger, G., Geider, K., Popp, B., Tamer, C., Stefanova, I., …
Kutsche, K. (2010). Mutations in GRIN2A and GRIN2B encoding regulatory subunits
of NMDA receptors cause variable neurodevelopmental phenotypes. Nature
Genetics, 42(11), 1021–1026. https://doi.org/10.1038/ng.677
Erreger K., and Traynelis S.F. 2008. Zinc inhibition of rat NR1/NR2A N-methyl-Daspartate receptors. J. Physiol. 586:763–778. 10.1113/jphysiol.2007.143941 [PMC
free article] [PubMed] [CrossRef] [Google Scholar]
Erreger K., Chen P.E., Wyllie D.J., and Traynelis S.F. 2004. Glutamate receptor
gating. Crit. Rev. Neurobiol. 16:187–224. 10.1615/CritRevNeurobiol.v16.i3.10
[PubMed] [CrossRef] [Google Scholar]

77

Erreger K., Geballe M.T., Kristensen A., Chen P.E., Hansen K.B., Lee C.J., Yuan H.,
Le P., Lyuboslavsky P.N., Micale N., et al. 2007. Subunit-specific agonist activity at
NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate
receptors. Mol. Pharmacol. 72:907–920. 10.1124/mol.107.037333 [PubMed]
[CrossRef] [Google Scholar]
Ferreira A. (2012). Calpain dysregulation in Alzheimer's disease. ISRN Biochem.
2012:728571. 10.5402/2012/728571 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Fong D. K., Rao A., Crump F. T., and Craig A. M. (2002) Rapid synaptic remodeling
by protein kinase C: reciprocal translocation of NMDA receptors and
calcium/calmodulin-dependent kinase II. J. Neurosci. 22, 2153–2164 [PubMed]
[Google Scholar]
Fossat P., Turpin F. R., Sacchi S., Dulong J., Shi T., Rivet J. M., et al. (2012). Glial Dserine gates NMDA receptors at excitatory synapses in prefrontal cortex. Cereb.
Cortex 22 595–606. 10.1093/cercor/bhr130 [PubMed] [CrossRef] [Google Scholar]
Foster A.C., Farnsworth J., Lind G.E., Li Y.X., Yang J.Y., Dang V., Penjwini M.,
Viswanath V., Staubli U., Kavanaugh M.P. D-serine is a substrate for neutral amino
acid transporters asct1/slc1a4 and asct2/slc1a5, and is transported by both subtypes
in rat hippocampal astrocyte cultures. PLoS ONE. 2016;11:e0156551. doi:
10.1371/journal.pone.0156551. [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Frasca A., Aalbers M., Frigerio F., Fiordaliso F., Salio M., Gobbi M., et al. . (2011).
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol.
Dis. 43, 507–515. 10.1016/j.nbd.2011.04.024 [PubMed] [CrossRef] [Google Scholar]
Fukasawa Y, Segawa H, Kim JY, Chairoungdua A, Kim DK, Matsuo H et al. (2000)
Identification and characterization of a Na(+)-independent neutral amino acid
transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity
for small neutral D- and L-amino acids. J Biol Chem. 275:9690–8. . [PubMed] [Google
Scholar]
Furukawa H., and Gouaux E. 2003. Mechanisms of activation, inhibition and
specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO
J. 22:2873–2885. 10.1093/emboj/cdg303 [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
Furukawa H., Singh S.K., Mancusso R., and Gouaux E. 2005. Subunit arrangement
and function in NMDA receptors. Nature. 438:185–192. 10.1038/nature04089
[PubMed] [CrossRef] [Google Scholar]

78

Gao, K., Tankovic, A., Zhang, Y., Kusumoto, H., Zhang, J., Chen, W., … Jiang, Y.
(2017). Adenovo loss-of-function GRIN2A mutation associated with childhood focal
epilepsy and acquired epileptic aphasia. PLoS ONE, 12(2), 1–20.
https://doi.org/10.1371/journal.pone.0170818
Glasgow N.G., Povysheva N.V., Azofeifa A.M., and Johnson J.W. 2017. Memantine
and Ketamine Differentially Alter NMDA Receptor Desensitization. J. Neurosci.
37:9686–9704. 10.1523/JNEUROSCI.1173-17.2017 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Glasgow N.G., Siegler Retchless B., and Johnson J.W. 2015. Molecular bases of
NMDA receptor subtype-dependent properties. J. Physiol. 593:83–95.
10.1113/jphysiol.2014.273763 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Granger A.J., and Nicoll R.A. 2013. Expression mechanisms underlying long-term
potentiation: a postsynaptic view, 10 years on. Philos. Trans. R. Soc. Lond. B Biol.
Sci. 369:20130136 10.1098/rstb.2013.0136 [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
Gray J.A., Shi Y., Usui H., During M.J., Sakimura K., and Nicoll R.A. 2011. Distinct
modes of AMPA receptor suppression at developing synapses by GluN2A and
GluN2B: single-cell NMDA receptor subunit deletion in vivo. Neuron. 71:1085–1101.
10.1016/j.neuron.2011.08.007 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Hackos D.H., and Hanson J.E. 2017. Diverse modes of NMDA receptor positive
allosteric modulation: Mechanisms and consequences. Neuropharmacology. 112(Pt
A):34–45. 10.1016/j.neuropharm.2016.07.037 [PubMed] [CrossRef] [Google Scholar]
Hackos D.H., Lupardus P.J., Grand T., Chen Y., Wang T.M., Reynen P., Gustafson
A., Wallweber H.J., Volgraf M., Sellers B.D., et al. 2016. Positive Allosteric
Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and
Impacts on Circuit Function. Neuron. 89:983–999. 10.1016/j.neuron.2016.01.016
[PubMed] [CrossRef] [Google Scholar]
Hansen K.B., Bräuner-Osborne H., and Egebjerg J. 2008. Pharmacological
characterization of ligands at recombinant NMDA receptor subtypes by
electrophysiological recordings and intracellular calcium measurements. Comb.
Chem. High Throughput Screen. 11:304–315. 10.2174/138620708784246040
[PubMed] [CrossRef] [Google Scholar]
Hansen K.B., Ogden K.K., Yuan H., and Traynelis S.F. 2014. Distinct functional and
pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA
receptors. Neuron. 81:1084–1096. 10.1016/j.neuron.2014.01.035 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]

79

Hansen KB, Ogden KK, Traynelis SF. Subunit-selective allosteric inhibition of glycine
binding to NMDA receptors. J Neurosci 2012; 32: 6197–208. [PMC free article]
[PubMed] [Google Scholar]
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. .
Decreased serum levels of D-serine in patients with schizophrenia: evidence in
support of the N-methyl-D-aspartate receptor hypofunction hypothesis of
schizophrenia. Arch Gen Psychiatry. (2003) 60:572–6. 10.1001/archpsyc.60.6.572
[PubMed] [CrossRef] [Google Scholar]
Hasler G. (2010). Pathophysiology of depression: do we have any solid evidence of
interest to clinicians?. World psychiatry : official journal of the World Psychiatric
Association (WPA), 9(3), 155–161.
Hayashi Y., Shi S. H., Esteban J. A., Piccini A., Poncer J. C., Malinow R. (2000).
Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1
and PDZ domain interaction. Science 287, 2262–2267.
10.1126/science.287.5461.2262 [PubMed] [CrossRef] [Google Scholar]
Helboe L, Egebjerg J, Moller M, Thomsen C. Distribution and pharmacology of
alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. European Journal of
Neuroscience. 2003;18:2227–2238. doi: 10.1046/j.1460-9568.2003.02966.x.
[PubMed] [CrossRef] [Google Scholar]
Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends
on release of d-serine from astrocytes.(2010) Nature. 2010;463:232–236. doi:
10.1038/nature08673. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Hestrin S., Nicoll R.A., Perkel D.J., and Sah P. 1990. Analysis of excitatory synaptic
action in pyramidal cells using whole-cell recording from rat hippocampal slices. J.
Physiol. 422:203–225. 10.1113/jphysiol.1990.sp017980 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Homayoun, H., & Moghaddam, B. (2007). NMDA receptor hypofunction produces
opposite effects on prefrontal cortex interneurons and pyramidal neurons. The
Journal of neuroscience : the official journal of the Society for Neuroscience, 27(43),
11496–11500. doi:10.1523/JNEUROSCI.2213-07.2007
Huang X, et al. D-Serine regulates proliferation and neuronal differentiation of neural
stem cells from postnatal mouse forebrain. CNS Neurosci Ther. 2012;18:4–13. doi:
10.1111/j.1755-5949.2011.00276.x. [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Ittner L. M., Ke Y. D., Delerue F., Bi M., Gladbach A., van Eersel J., et al. (2010).
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse

80

models. Cell 142 387–397. 10.1016/j.cell.2010.06.036 [PubMed] [CrossRef] [Google
Scholar]
Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y., et al. (2006).
Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the
extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal
neurons. J. Physiol. 572 789–798. 10.1113/jphysiol.2006.105510 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Johnson J.W., and Ascher P. 1987. Glycine potentiates the NMDA response in
cultured mouse brain neurons. Nature. 325:529–531. 10.1038/325529a0 [PubMed]
[CrossRef] [Google Scholar]
Jones E. G., Huntley G. W., Benson D. L. (1994). Alpha calcium/calmodulindependent protein kinase II selectively expressed in a subpopulation of excitatory
neurons in monkey sensory-motor cortex: comparison with GAD-67 expression. J.
Neurosci. 14, 611–629.
Jurado S, et al. LTP requires a unique postsynaptic SNARE fusion machinery.
Neuron. 2013;77:542–558. doi: 10.1016/j.neuron.2012.11.029. [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Kaiser T.M., Kell S.A., Kusumoto H., Shaulsky G., Bhattacharya S., Epplin M.P.,
Strong K.L., Miller E.J., Cox B.D., Menaldino D.S., et al. 2018. The Bioactive ProteinLigand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to
the NMDA Receptor. Mol. Pharmacol. 93:141–156. 10.1124/mol.117.110940 [PMC
free article] [PubMed] [CrossRef] [Google Scholar]
Karakas E., and Furukawa H. 2014. Crystal structure of a heterotetrameric NMDA
receptor ion channel. Science. 344:992–997. 10.1126/science.1251915 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Karakas E., Regan M.C., and Furukawa H. 2015. Emerging structural insights into
the function of ionotropic glutamate receptors. Trends Biochem. Sci. 40:328–337.
10.1016/j.tibs.2015.04.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Karakas E., Simorowski N., and Furukawa H. 2009. Structure of the zinc-bound
amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J. 28:3910–
3920. 10.1038/emboj.2009.338 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Kazi R., Gan Q., Talukder I., Markowitz M., Salussolia C.L., and Wollmuth L.P. 2013.
Asynchronous movements prior to pore opening in NMDA receptors. J. Neurosci.
33:12052–12066. 10.1523/JNEUROSCI.5780-12.2013 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]

81

Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic
targets in depression and mood disorders. Expert opinion on therapeutic targets.
2005;9(1):153–68. Epub 2005/03/11. doi: 10.1517/14728222.9.1.153 . [PubMed]
[Google Scholar]
Khatri A., Burger P.B., Swanger S.A., Hansen K.B., Zimmerman S., Karakas E.,
Liotta D.C., Furukawa H., Snyder J.P., and Traynelis S.F. (2014). Structural
determinants and mechanism of action of a GluN2C-selective NMDA receptor
positive allosteric modulator. Mol. Pharmacol. 86:548–560. 10.1124/mol.114.094516
[PMC free article] [PubMed] [CrossRef] [Google Scholar]
Khatri A., Burger P.B., Swanger S.A., Hansen K.B., Zimmerman S., Karakas E.,
Liotta D.C., Furukawa H., Snyder J.P., and Traynelis S.F. 2014. Structural
determinants and mechanism of action of a GluN2C-selective NMDA receptor
positive allosteric modulator. Mol. Pharmacol. 86:548–560. 10.1124/mol.114.094516
[PMC free article] [PubMed] [CrossRef] [Google Scholar]
Kim PM, Aizawa H, Kim PS, Huang AS, Wickramasinghe SR, Kashani AH, et al.
Serine racemase: activation by glutamate neurotransmission via glutamate receptor
interacting protein and mediation of neuronal migration. Proc Nat Acad Sci USA.
(2005) 6:2105–10. 10.1073/pnas.0409723102 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Kleckner N.W., and Dingledine R. 1988. Requirement for glycine in activation of
NMDA-receptors expressed in Xenopus oocytes. Science. 241:835–837.
10.1126/science.2841759 [PubMed] [CrossRef] [Google Scholar]
Kotermanski S.E., and Johnson J.W. 2009. Mg2+ imparts NMDA receptor subtype
selectivity to the Alzheimer’s drug memantine. J. Neurosci. 29:2774–2779.
10.1523/JNEUROSCI.3703-08.2009 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Krebs HA. Metabolism of amino-acids: Deamination of amino-acids. Biochem J.
1935;29:1620–1644. doi: 10.1042/bj0291620. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., et al. .
(1992). Molecular diversity of the NMDA receptor channel. Nature 358, 36–41.
10.1038/358036a0 [PubMed] [CrossRef] [Google Scholar]
Labrie V, et al. Serine racemase is associated with schizophrenia susceptibility in
humans and in a mouse model. (2009)Hum. Mol. Genet. 2009;18:3227–3243. doi:
10.1093/hmg/ddp261. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

82

Lan JY, Skeberdis VA, Jover T, Grooms SY, Lin Y, Araneda RC, Zheng X, Bennett
MV, Zukin RS. (2001) Protein kinase C modulates NMDA receptor trafficking and
gating. Nat Neurosci 4:382–390. [PubMed] [Google Scholar]
Lavezzari G, Mccallum J, Dewey CM, Roche KW. Subunit-specific regulation of
NMDA receptor endocytosis. J. Neurosci. 2004;24:6383–6391. doi:
10.1523/JNEUROSCI.1890-04.2004. [PubMed] [CrossRef] [Google Scholar]
Lee CH, Gouaux E. Amino terminal domains of the NMDA receptor are organized as
local heterodimers. (2011) PLoS ONE. 2011;6:e19180. [PMC free article] [PubMed]
[Google Scholar]
Lee, Y. J., Hwang, S. K., & Kwon, S. (2017). The Clinical Spectrum of Benign
Epilepsy with Centro-Temporal Spikes: a Challenge in Categorization and
Predictability. Journal of epilepsy research, 7(1), 1–6. doi:10.14581/jer.17001
Lemke, Johannes R, Dennis Lal, Eva M Reinthaler, Isabelle Steiner, Michael
Nothnagel, Michael Alber, Kirsten Geider, Bodo Laube, Michael Schwake, Katrin
Finsterwalder, Andre Franke, Markus Schilhabel, Johanna A Jähn, Hiltrud Muhle,
Rainer Boor, Wim Van Paesschen, Roberto Caraballo, Natalio Fejerman, Sarah
Weckhuysen, Peter De Jonghe, Jan Larsen, Rikke S Møller, Helle Hjalgrim, Laura
Addis, Shan Tang, Elaine Hughes, Deb K Pal, Kadi Veri, Ulvi Vaher, Tiina Talvik,
Petia Dimova, Rosa Guerrero López, José M Serratosa, Tarja Linnankivi, Anna-Elina
Lehesjoki, Susanne Ruf, Markus Wolff, Sarah Buerki, Gabriele Wohlrab, Judith
Kroell, Alexandre N Datta, Barbara Fiedler, Gerhard Kurlemann, Gerhard Kluger,
Andreas Hahn, D Edda Haberlandt, Christina Kutzer, Jürgen Sperner, Felicitas
Becker, Yvonne G Weber, Martha Feucht, Hannelore Steinböck, Birgit Neophythou,
Gabriel M Ronen, Ursula Gruber-Sedlmayr, Julia Geldner, Robert J Harvey, Per
Hoffmann, Stefan Herms, Janine Altmüller, Mohammad R Toliat, Holger Thiele, Peter
Nürnberg, Christian Wilhelm, Ulrich Stephani, Ingo Helbig, Holger Lerche, Fritz
Zimprich, Bernd A Neubauer, Saskia Biskup & Sarah von Spiczak. “Mutations in
GRIN2A Cause Idiopathic Focal Epilepsy with Rolandic Spikes.” Nature Genetics 45
(August 11, 2013): 1067. http://dx.doi.org/10.1038/ng.2728
Lester R.A., and Jahr C.E. 1992. NMDA channel behavior depends on agonist
affinity. J. Neurosci. 12:635–643. 10.1523/JNEUROSCI.12-02-00635.1992 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Lester R.A., Clements J.D., Westbrook G.L., and Jahr C.E. 1990. Channel kinetics
determine the time course of NMDA receptor-mediated synaptic currents. Nature.
346:565–567. 10.1038/346565a0 [PubMed] [CrossRef] [Google Scholar]
Leveille F., El gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., et al. (2008).
Neuronal viability is controlled by a functional relation between synaptic and

83

extrasynaptic NMDA receptors. FASEB J. 22 4258–4271. 10.1096/fj.08-107268
[PubMed] [CrossRef] [Google Scholar]
Lewis D. A. (2012). Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions. The European journal of neuroscience,
35(12), 1871–1878. doi:10.1111/j.1460-9568.2012.08156.x
Li M, Pevny L, Lovell-Badge R, Smith A. Generation of purified neural precursors
from embryonic stem cells by lineage selection. Curr Biol. 1998;8:971–974. doi:
10.1016/S0960-9822(98)70399-9. [PubMed] [CrossRef] [Google Scholar]
Li N, Lee B, Liu RJ, et al. : mTOR-dependent synapse formation underlies the rapid
antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–64.
10.1126/science.1190287 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
F1000 Recommendation
Li S et al., Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term
depression by disrupting neuronal glutamate uptake. Neuron 62, 788–801 (2009).
[PMC free article] [PubMed] [Google Scholar]
Li S., Jin M., Koeglsperger T., Shepardson N. E., Shankar G. M., Selkoe D. J. (2011).
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving
excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci,
31(18), 6627–6638. doi:10.1523/JNEUROSCI.0203-11.2011 [PMC free article]
[PubMed] [Google Scholar]
Li Y, Krupa B, Kang JS, Bolshakov VY, Liu G. Glycine site of NMDA receptor serves
as a spatiotemporal detector of synaptic activity patterns. (2009)J Neurophysiol 102:
578–589, 2009. doi:10.1152/jn.91342.2008. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
Li, Y., Sacchi, S., Pollegioni, L., Basu, A. C., Coyle, J. T., & Bolshakov, V. Y. (2013).
Identity of endogenous NMDAR glycine site agonist in amygdala is determined by
synaptic activity level. Nature communications, 4, 1760. doi:10.1038/ncomms2779
Lind G.E., Mou T.C., Tamborini L., Pomper M.G., De Micheli C., Conti P., Pinto A.,
and Hansen K.B. 2017. Structural basis of subunit selectivity for competitive NMDA
receptor antagonists with preference for GluN2A over GluN2B subunits. Proc. Natl.
Acad. Sci. USA. 114:E6942–E6951. 10.1073/pnas.1707752114 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Lisman J. A mechanism for the Hebb and anti-Hebb processes underlying learning
and memory. Proc Natl Acad Sci U S A. 1989;86:9574–9578. [PMC free article]
[PubMed] [Google Scholar]

84

Liu J., Chang L., Roselli F., Almeida O. F. X., Gao X., Wang X., et al. (2010).
Amyloid-β induces caspase-dependent loss of PSD-95 and synaptophysin through
NMDA receptors. J. Alzheimers Dis. 22 541–556. 10.3233/JAD-2010-100948
[PubMed] [CrossRef] [Google Scholar]
Liu, Y., T.P. Wong, M. Aarts, A. Rooyakkers, L. Liu, T.W. Lai, D.C. Wu, J. Lu, M.
Tymianski, A.M. Craig, Y.T. WangNMDA receptor subunits have differential roles in
mediating excitotoxic neuronal death both in vitro and in vivo J. Neurosci., 27 (11)
(2007), pp. 2846-2857 CrossRefView Record in ScopusGoogle Scholar
Lodge, D., Watkins, J. C., Bortolotto, Z. A., Jane, D. E., & Volianskis, A. (2019). The
1980s: D-AP5, LTP and a Decade of NMDA Receptor Discoveries. Neurochemical
research, 44(3), 516–530. doi:10.1007/s11064-018-2640-6
Luo J., Wang Y., Yasuda R.P., Dunah A.W., and Wolfe B.B. 1997. The majority of Nmethyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least
three different subunits (NR1/NR2A/NR2B). Mol. Pharmacol. 51:79–86.
10.1124/mol.51.1.79 [PubMed] [CrossRef] [Google Scholar]
Lüscher C., Malenka R. C. (2012). NMDA receptor-dependent long-term potentiation
and long-term depression (LTP/LTD). Cold Spring Harb. Perspect. Biol. 4, 1–15.
10.1101/cshperspect.a005710 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Lussier M.P., Sanz-Clemente A., and Roche K.W. 2015. Dynamic Regulation of NMethyl-d-aspartate (NMDA) and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic
Acid (AMPA) Receptors by Posttranslational Modifications. J. Biol. Chem.
290:28596–28603. 10.1074/jbc.R115.652750 [PMC free article] [PubMed] [CrossRef]
[Google Scholar]
MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. (1987) NMDAreceptor activation increases cytoplasmic calcium concentration in cultured spinal
cord neurones. Nature. 1986;321:519–522. doi: 10.1038/321519a0. [PubMed]
[CrossRef] [Google Scholar]
Mann JJ. The medical management of depression. N Engl J Med. 2005;353:1819–
1834. doi: 10.1056/NEJMra050730. [PubMed] [CrossRef] [Google Scholar]
Marchetti M, et al. ATP binding to human serine racemase is cooperative and
modulated by glycine. (2013) FEBS J. 2013;280:5853–5863. doi:
10.1111/febs.12510. [PubMed] [CrossRef] [Google Scholar]
Margaill, I., S. Parmentier, J. Callebert, M. Allix, R.G. Boulu, M. PlotkineShort
therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive
rats J. Cereb. Blood Flow Metab., 16 (1) (1996), pp. 107-113 View Record in
ScopusGoogle Scholar

85

McKay, S., Ryan, T. J., McQueen, J., Indersmitten, T., Marwick, K., Hasel, P., …
Komiyama, N. H. (2018). The Developmental Shift of NMDA Receptor Composition
Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences.
Cell reports, 25(4), 841–851.e4. doi:10.1016/j.celrep.2018.09.089
Moghaddam B, Javitt D. 2012. From revolution to evolution: the glutamate hypothesis
of schizophrenia and its implication for treatment. Neuropsychopharmacology 37: 415 [PMC free article] [PubMed]
Montastruc JL, Rascol O, Senard JM, Rascol A. A pilot study of N-methyl-D-aspartate
(NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry.
1992;55:630–631. [PMC free article] [PubMed] [Google Scholar]
Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. 1994.
Developmental and regional expression in the rat brain and functional properties of
four NMDA receptors. Neuron. 12:529–540. 10.1016/0896-6273(94)90210-0
[PubMed] [CrossRef] [Google Scholar]
Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N.,
Sakmann B., and Seeburg P.H. 1992. Heteromeric NMDA receptors: molecular and
functional distinction of subtypes. Science. 256:1217–1221.
10.1126/science.256.5060.1217 [PubMed] [CrossRef] [Google Scholar]
Mothet J.P., Le Bail M., and Billard J.M. 2015. Time and space profiling of NMDA
receptor co-agonist functions. J. Neurochem. 135:210–225. 10.1111/jnc.13204
[PubMed] [CrossRef] [Google Scholar]
Mothet, J. P., Parent, A. T., Wolosker, H., Brady, R. O., Jr, Linden, D. J., Ferris, C.
D., … Snyder, S. H. (2000). D-serine is an endogenous ligand for the glycine site of
the N-methyl-D-aspartate receptor. Proceedings of the National Academy of
Sciences of the United States of America, 97(9), 4926–4931.
doi:10.1073/pnas.97.9.4926
Musante V., Summa M., Cunha R. A., Raiteri M., Pittaluga A. (2011). Pre-synaptic
glycine GlyT1 transporter-NMDA receptor interaction: relevance to NMDA
autoreceptor activation in the presence of Mg2+ ions. J. Neurochem. 117 516–527.
10.1111/j.1471-4159.2011.07223.x [PubMed] [CrossRef] [Google Scholar]
Mustafa A. K., Ahmad A. S., Zeynalov E., Gazi S. K., Sikka G., Ehmsen J. T., et al. .
(2010). Serine racemase deletion protects against cerebral ischemia and
excitotoxicity. J. Neurosci. 30, 1413–1416. 10.1523/JNEUROSCI.4297-09.2010
[PMC free article] [PubMed] [CrossRef] [Google Scholar]
Nakauchi J, et al. Cloning and characterization of a human brain Na(+)-independent
transporter for small neutral amino acids that transports D-serine with high affinity.

86

(2000) Neurosci. Lett. 2000;287:231–235. doi: 10.1016/S0304-3940(00)01169-1.
[PubMed] [CrossRef] [Google Scholar]
Nicoll RA. A brief history of long-term potentiation (2017). Neuron. 2017;93:281–290.
[PubMed] [Google Scholar]
Nong Y, et al. Glycine binding primes NMDA receptor internalization. (2003) Nature.
2003;422:302–307. doi: 10.1038/nature01497. [PubMed] [CrossRef] [Google Scholar]
Ogden K.K., Chen W., Swanger S.A., McDaniel M.J., Fan L.Z., Hu C., Tankovic A.,
Kusumoto H., Kosobucki G.J., Schulien A.J., et al. 2017. Molecular Mechanism of
Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential
Rescue Pharmacology. PLoS Genet. 13:e1006536 10.1371/journal.pgen.1006536
[PMC free article] [PubMed] [CrossRef] [Google Scholar]
Okabe S., Miwa A., Okado H. (1999). Alternative splicing of the C-terminal domain
regulates cell surface expression of the NMDA receptor NR1 subunit. J. Neurosci. 19
7781–7792. 10.1523/JNEUROSCI.19-18-07781.1999 [PubMed] [CrossRef] [Google
Scholar]
Opitz-Araya, X. & Barria, A. Organotypic hippocampal slice cultures. J Vis Exp,
10.3791/2462 (2011). [PMC free article] [PubMed]
Paetau R. Magnetoencephalography in Landau-Kleffner syndrome. Epilepsia.
2009;50( Suppl 7):51–4. [PubMed] [Google Scholar]
Pahk A.J., and Williams K. 1997. Influence of extracellular pH on inhibition by
ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci. Lett.
225:29–32. 10.1016/S0304-3940(97)00176-6 [PubMed] [CrossRef] [Google Scholar]
Panatier A., Theodosis D. T., Mothet J. P., Touquet B., Pollegioni L., Poulain D. A., et
al. (2006b). Glia-derived D-serine controls NMDA receptor activity and synaptic
memory. Cell 125 775–784. 10.1016/j.cell.2006.02.051 [PubMed] [CrossRef] [Google
Scholar]
Paoletti P., Bellone C., and Zhou Q. 2013. NMDA receptor subunit diversity: impact
on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14:383–
400. 10.1038/nrn3504 [PubMed] [CrossRef] [Google Scholar]
Papouin T., Ladépêche L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L.,
Pollegioni L., Mothet J.P., and Oliet S.H. 2012. Synaptic and extrasynaptic NMDA
receptors are gated by different endogenous coagonists. Cell. 150:633–646.
10.1016/j.cell.2012.06.029 [PubMed] [CrossRef] [Google Scholar]
Paupard M.C., Friedman L.K., and Zukin R.S. 1997. Developmental regulation and
cell-specific expression of N-methyl-D-aspartate receptor splice variants in rat

87

hippocampus. Neuroscience. 79:399–409. 10.1016/S0306-4522(96)00677-X
[PubMed] [CrossRef] [Google Scholar]
Pérez-Otaño I., Ehlers M. D. (2005). Homeostatic plasticity and NMDA receptor
trafficking. Trends Neurosci. 28 229–238. 10.1016/j.tins.2005.03.004 [PubMed]
[CrossRef] [Google Scholar]
Pérez-Otaño I., Larsen R.S., and Wesseling J.F. 2016. Emerging roles of GluN3containing NMDA receptors in the CNS. Nat. Rev. Neurosci. 17:623–635.
10.1038/nrn.2016.92 [PubMed] [CrossRef] [Google Scholar]
Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. (2013) Genic intolerance
to functional variation and the interpretation of personal genomes. PLoS Genet
9:e1003709. PMC3749936
Peyrovian, B., Rosenblat, JD., Pan Z., Iacobucci., M., Brietzke E., McIntyre, RS.
(2019) Prog Neuropsychopharmacol Biol Psychiatry Jun 8;92:387-404. doi:
10.1016/j.pnpbp.2019.02.001. Epub 2019 Feb 6.
Pierson Tyler Mark, Yuan Hongjie, Marsh Eric D., Fuentes‐Fajardo Karin, Adams
David R., Markello Thomas, Golas Gretchen, Simeonov, D. R., Holloman, C. ,
Tankovic, A. , Karamchandani, M. M., Schreiber, J. M., Mullikin, J. C., Tifft, C. J.,
Toro, C. , Boerkoel, C. F., Traynelis, S. F. and Gahl, W.A. “GRIN2A Mutation and
Early‐onset Epileptic Encephalopathy: Personalized Therapy with Memantine.”
Annals of Clinical and Translational Neurology 1, no. 3 (March 14, 2014): 190–98.
https://doi.org/10.1002/acn3.39.
Pollegioni L, Sacchi S. Metabolism of the neuromodulator D-serine. Cell Mol Life Sci.
2010;67:2387–2404. doi: 10.1007/s00018-010-0307-9. [PubMed] [CrossRef] [Google
Scholar]
Quinlan EM, Olstein DH, Bear MF. Bidirectional, experience-dependent regulation of
N-methyl-D-aspartate receptor subunit composition in the rat visual cortex during
postnatal development. PNAS. 1999a;96:12876–12880. doi:
10.1073/pnas.96.22.12876. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Quinlan EM, Philpot BD, Huganir RL, Bear MF. Rapid, experience-dependent
expression of synaptic NMDA receptors in visual cortex in vivo. Nature Neuroscience.
1999b;2:352–357. doi: 10.1038/7263. [PubMed] [CrossRef] [Google Scholar]
Rao A., Craig A. M. (1997). Activity regulates the synaptic localization of the NMDA
receptor in hippocampal neurons. Neuron 19, 801–812. 10.1016/s08966273(00)80962-9 [PubMed] [CrossRef] [Google Scholar]

88

Rauner C., and Köhr G. 2011. Triheteromeric NR1/NR2A/NR2B receptors constitute
the major N-methyl-D-aspartate receptor population in adult hippocampal synapses.
J. Biol. Chem. 286:7558–7566. 10.1074/jbc.M110.182600 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Regan M.C., Grant T., McDaniel M.J., Karakas E., Zhang J., Traynelis S.F., Grigorieff
N., and Furukawa H. 2018. Structural Mechanism of Functional Modulation by Gene
Splicing in NMDA Receptors. Neuron. 98:521–529.e523. [PMC free article] [PubMed]
[Google Scholar]
Ren H., Honse Y., Karp B.J., Lipsky R.H., and Peoples R.W. 2003. A site in the fourth
membrane-associated domain of the N-methyl-D-aspartate receptor regulates
desensitization and ion channel gating. J. Biol. Chem. 278:276–283.
10.1074/jbc.M209486200 [PubMed] [CrossRef] [Google Scholar]
Riou M, Stroebel D, Edwardson JM, Paoletti P. An alternating GluN1-2-1-2 subunit
arrangement in mature NMDA receptors. PLoS One. 2012;7:e35134. [PMC free
article] [PubMed] [Google Scholar]
Ronicke R., Mikhaylova M., Ronicke S. Early neuronal dysfunction by amyloid beta
oligomers depends on activation of NR2B-containing NMDA receptors. (2011)
Neurobiol. Aging. 2011;32:2219–2228. [PubMed] [Google Scholar]
Rosenberg D, et al. Neuronal D-serine and glycine release via the Asc-1 transporter
regulates NMDA receptor-dependent synaptic activity. (2013) J Neurosci.
2013;33:3533–3544. [PMC free article] [PubMed] [Google Scholar]
Rumbaugh G., Prybylowski K., Wang J.F., and Vicini S. 2000. Exon 5 and spermine
regulate deactivation of NMDA receptor subtypes. J. Neurophysiol. 83:1300–1306.
10.1152/jn.2000.83.3.1300 [PubMed] [CrossRef] [Google Scholar]
Rutter AR, et al. Evidence from gene knockout studies implicates Asc-1 as the
primary transporter mediating d-serine reuptake in the mouse CNS. The European
journal of neuroscience. 2007;25:1757–1766. doi: 10.1111/j.14609568.2007.05446.x. [PubMed] [CrossRef] [Google Scholar]
Sakimura K., Kutsuwada T., Ito I., Manabe T., Takayama C., Kushiya E., et al. .
(1995). Reduced hippocampal LTP and spatial learning in mice lacking NMDA
receptor epsilon 1 subunit. Nature 373, 151–155. 10.1038/373151a0 [PubMed]
[CrossRef] [Google Scholar]
Sakimura, K., T. Kutsuwada, I. Ito, T. Manabe, C. Takayama, E. Kushiya, T. Yagi, S.
Aizawa, Y. Inoue, H. Sugiyama, et al. Reduced hippocampal LTP and spatial learning
in mice lacking NMDA receptor epsilon 1 subunit Nature, 373 (1995), pp. 151-155
Salmi, M, Del Gallo, F, Minlebaev, M, et al. Impaired vocal communication, sleep‐
related discharges, and transient alteration of slow‐wave sleep in developing mice

89

lacking the GluN2A subunit of N‐methyl‐D‐aspartate receptors. Epilepsia. 2019; 60:
1424– 1437. https://doi.org/10.1111/epi.16060
Sason H., Billard J. M., Smith G. P., Safory H., Neame S., Kaplan E., et al. . (2017).
Asc-1 transporter regulation of synaptic activity via the tonic release of d-serine in the
forebrain. Cereb. Cortex 27, 1573–1587. 10.1093/cercor/bhv350 [PubMed]
[CrossRef] [Google Scholar]
Sather W., Dieudonné S., MacDonald J.F., and Ascher P. 1992. Activation and
desensitization of N-methyl-D-aspartate receptors in nucleated outside-out patches
from mouse neurones. J. Physiol. 450:643–672. 10.1113/jphysiol.1992.sp019148
[PMC free article] [PubMed] [CrossRef] [Google Scholar]
Schneggenburger R., and Ascher P. 1997. Coupling of permeation and gating in an
NMDA-channel pore mutant. Neuron. 18:167–177. 10.1016/S0896-6273(01)80055-6
[PubMed] [CrossRef] [Google Scholar]
Schorge S., Elenes S., and Colquhoun D. 2005. Maximum likelihood fitting of single
channel NMDA activity with a mechanism composed of independent dimers of
subunits. J. Physiol. 569:395–418. 10.1113/jphysiol.2005.095349 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Scott D.B., Blanpied T.A., and Ehlers M.D. 2003. Coordinated PKA and PKC
phosphorylation suppresses RXR-mediated ER retention and regulates the surface
delivery of NMDA receptors. Neuropharmacology. 45:755–767. 10.1016/S00283908(03)00250-8 [PubMed] [CrossRef] [Google Scholar]
Scott D.B., Blanpied T.A., Swanson G.T., Zhang C., and Ehlers M.D. 2001. An NMDA
receptor ER retention signal regulated by phosphorylation and alternative splicing. J.
Neurosci. 21:3063–3072. 10.1523/JNEUROSCI.21-09-03063.2001 [PubMed]
[CrossRef] [Google Scholar]
Seeburg P.H., Burnashev N., Köhr G., Kuner T., Sprengel R., and Monyer H. 1995.
The NMDA receptor channel: molecular design of a coincidence detector. Recent
Prog. Horm. Res. 50:19–34. [PubMed] [Google Scholar]
Simon, RP., J.H. Swan, T. Griffiths, B.S. MeldrumBlockade of N-methyl-D-aspartate
receptors may protect against ischemic damage in the brain Science, 226 (4676)
(1984), pp. 850-852 View Record in ScopusGoogle Scholar
Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of
an AMPA-subtype glutamate receptor. Nature. 2009;462:745–756. doi:
10.1038/nature08624. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Stevens ER, Gustafson EC. Miller RF. Glycine transport accounts for the differential
role of glycine vs. D-serine at NMDA receptor coagonist sites in the salamander

90

retina. Eur J Neurosci. 2010;31:808–816. [PMC free article] [PubMed] [Google
Scholar]
Sun W., Hansen K.B., and Jahr C.E. 2017. Allosteric Interactions between NMDA
Receptor Subunits Shape the Developmental Shift in Channel Properties. Neuron.
94:58–64.e53. [PMC free article] [PubMed] [Google Scholar]
Sun Y., Olson R., Horning M., Armstrong N., Mayer M., and Gouaux E. 2002.
Mechanism of glutamate receptor desensitization. Nature. 417:245–253.
10.1038/417245a [PubMed] [CrossRef] [Google Scholar]
Swanger, Sharon A., Wenjuan Chen, Gordon Wells, Pieter B. Burger, Anel Tankovic,
Subhrajit Bhattacharya, Katie L. Strong, Chun Hu, Hirofumi Kusumoto, Jing Zhang,
David R. Adams, John J. Millichap, Slavé Petrovski, Stephen F. Traynelis, Hongjie
Yuan,. “Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in
the GluN2A and GluN2B Agonist Binding Domains.” American Journal of Human
Genetics 99, no. 6 (December 1, 2016): 1261–80.
https://doi.org/10.1016/j.ajhg.2016.10.002.
Talukder I., Borker P., and Wollmuth L.P. 2010. Specific sites within the ligandbinding domain and ion channel linkers modulate NMDA receptor gating. J. Neurosci.
30:11792–11804. 10.1523/JNEUROSCI.5382-09.2010 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Tovar K.R., and Westbrook G.L. 1999. The incorporation of NMDA receptors with a
distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci.
19:4180–4188. 10.1523/JNEUROSCI.19-10-04180.1999 [PubMed] [CrossRef]
[Google Scholar]
Tovar K.R., McGinley M.J., and Westbrook G.L. 2013. Triheteromeric NMDA
receptors at hippocampal synapses. J. Neurosci. 33:9150–9160.
10.1523/JNEUROSCI.0829-13.2013 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Traynelis S.F., Hartley M., and Heinemann S.F. 1995. Control of proton sensitivity of
the NMDA receptor by RNA splicing and polyamines. Science. 268:873–876.
10.1126/science.7754371 [PubMed] [CrossRef] [Google Scholar]
Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K.,
Hansen K.B., Yuan H., Myers S.J., and Dingledine R. 2010. Glutamate receptor ion
channels: structure, regulation, and function. Pharmacol. Rev. 62:405–496.
10.1124/pr.109.002451 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Tu, W., X. Xu, L. Peng, X. Zhong, W. Zhang, M.M. Soundarapandian, C. Balel, M.
Wang, N. Jia, W. Zhang, F. Lew, S.L. Chan, Y. Chen, Y. LuDAPK1 interaction with

91

NMDA receptor NR2B subunits mediates brain damage in stroke Cell., 140 (2)
(2010), pp. 222-234 Article Download PDFView Record in ScopusGoogle Scholar
Ulbrich M.H., and Isacoff E.Y. 2007. Subunit counting in membrane-bound proteins.
Nat. Methods. 4:319–321. 10.1038/nmeth1024 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Vance K.M., Hansen K.B., and Traynelis S.F. 2012. GluN1 splice variant control of
GluN1/GluN2D NMDA receptors. J. Physiol. 590:3857–3875.
10.1113/jphysiol.2012.234062 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Vance K.M., Hansen K.B., and Traynelis S.F. 2013. Modal gating of GluN1/GluN2D
NMDA receptors. Neuropharmacology. 71:184–190.
10.1016/j.neuropharm.2013.03.018 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Vicini S., Wang J.F., Li J.H., Zhu W.J., Wang Y.H., Luo J.H., Wolfe B.B., and
Grayson D.R. 1998. Functional and pharmacological differences between
recombinant N-methyl-D-aspartate receptors. J. Neurophysiol. 79:555–566.
10.1152/jn.1998.79.2.555 [PubMed] [CrossRef] [Google Scholar]
Vincent Strehlow, Henrike O Heyne, Danique R M Vlaskamp, Katie F M Marwick,
Gabrielle Rudolf, Julitta de Bellescize, Saskia Biskup, Eva H Brilstra, Oebele F
Brouwer, Petra M C Callenbach, Julia Hentschel, Edouard Hirsch, Peter C Kind, Cyril
Mignot, Konrad Platzer, Patrick Rump, Paul A Skehel, David J A Wyllie, Giles E
Hardingham, Conny M A van Ravenswaaij-Arts, Gaetan Lesca, Johannes R Lemke,
GRIN2A study group, GRIN2A-related disorders: genotype and functional
consequence predict phenotype, Brain, Volume 142, Issue 1, January 2019, Pages
80–92, https://doi.org/10.1093/brain/awy304
Volkmann RA, et al. MPX-004 and MPX-007: New pharmacological tools to study the
physiology of NMDA receptors containing the GluN2A subunit. PLoS One.
2016;11:e0148129. [PMC free article] [PubMed] [Google Scholar]
Wake K, Yamazaki H, Hanzawa S, Konno R, Sakio H, Niwa A, et al. (2001)
Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methylD-aspartate receptor-mediated synaptic transmission in mutant mice lacking Damino-acid oxidase. Neurosci Lett 297: 25–28. [PubMed] [Google Scholar]
Watanabe A, et al. Serine racemase inhibition induces nitric oxide-mediated
neurovascular protection during cerebral ischemia. (2016) Neuroscience. (2016)
;339:139–149. doi: 10.1016/j.neuroscience.2016.09.036. [PubMed] [CrossRef]
[Google Scholar]

92

Watanabe K. Benign partial epilepsies. Wallace SJ, Farrell K, editors. Epilepsy in
children. 2nd ed. London: Arnold; 2004. p. 199–220.

Wenthold R.J., Prybylowski K., Standley S., Sans N., and Petralia R.S. 2003.
Trafficking of NMDA receptors. Annu. Rev. Pharmacol. Toxicol. 43:335–358.
10.1146/annurev.pharmtox.43.100901.135803 [PubMed] [CrossRef] [Google Scholar]
Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB. (1994) Sensitivity of the
N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol
Pharmacol 45:803–809 [PubMed] [Google Scholar]
Wolosker H, et al. Serine racemase: a glial enzyme synthesizing D-serine to regulate
glutamate-N-methyl-D-aspartate neurotransmission. (1999) Proc Natl Acad Sci U S
A. 1999;96:13409–13414. [PMC free article] [PubMed] [Google Scholar]
Wolosker H. 2007. NMDA receptor regulation by D-serine: new findings and
perspectives. Mol. Neurobiol. 36:152–164. 10.1007/s12035-007-0038-6 [PubMed]
[CrossRef] [Google Scholar]
Wyllie D.J., Béhé P., and Colquhoun D. 1998. Single-channel activations and
concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D
NMDA receptors. J. Physiol. 510:1–18. 10.1111/j.1469-7793.1998.001bz.x [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Wyllie D.J., Livesey M.R., and Hardingham G.E. 2013. Influence of GluN2 subunit
identity on NMDA receptor function. Neuropharmacology. 74:4–17.
10.1016/j.neuropharm.2013.01.016 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
XiangWei, W.; Jiang, Y.; Yuan, H. De Novo Mutations and Rare Variants Occurring in
NMDA Receptors. Curr. Opin. Physiol. 2018, 2, 27–35.
Xu, X. X., Liu, X. R., Fan, C. Y., Lai, J. X., Shi, Y. W., Yang, W., … Liao, W. P.
(2018). Functional Investigation of a GRIN2A Variant Associated with Rolandic
Epilepsy. Neuroscience Bulletin, 34(2), 237–246. https://doi.org/10.1007/s12264-0170182-6
Yang Y, Ge W, Chen Y, Zhang Z, Shen W, Wu C, et al. . (2003) Contribution of
astrocytes to hippocampal long-term potentiation through release of D-serine. Proc
Natl Acad Sci USA. (2003) 100:15194–9. 10.1073/pnas.2431073100 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Yang,Y., Q. Li, T. Yang, M. Hussain, A. Shuaib. Reduced brain infarct volume and
improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors
by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic

93

stroke model in rats J. Neurosurg., 98 (2) (2003), pp. 397-403 CrossRefView Record
in ScopusGoogle Scholar
Yi F., Mou T.C., Dorsett K.N., Volkmann R.A., Menniti F.S., Sprang S.R., and Hansen
K.B. 2016. Structural Basis for Negative Allosteric Modulation of GluN2A-Containing
NMDA Receptors. Neuron. 91:1316–1329. 10.1016/j.neuron.2016.08.014 [PMC free
article] [PubMed] [CrossRef] [Google Scholar]
Yi F., Traynelis S.F., and Hansen K.B. 2017. Selective Cell-Surface Expression of
Triheteromeric NMDA Receptors. Methods Mol. Biol. 1677:145–162. 10.1007/978-14939-7321-7_7 [PubMed] [CrossRef] [Google Scholar]
Yi F., Zachariassen L.G., Dorsett K.N., and Hansen K.B. 2018. Properties of
Triheteromeric N-Methyl-d-Aspartate Receptors Containing Two Distinct GluN1
Isoforms. Mol. Pharmacol. 93:453–467. 10.1124/mol.117.111427 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Yuan H., Hansen K.B., Vance K.M., Ogden K.K., and Traynelis S.F. 2009. Control of
NMDA receptor function by the NR2 subunit amino-terminal domain. J. Neurosci.
29:12045–12058. 10.1523/JNEUROSCI.1365-09.2009 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Yuan H., Hansen K.B., Zhang J., Pierson T.M., Markello T.C., Fajardo K.V., Holloman
C.M., Golas G., Adams D.R., Boerkoel C.F., et al. 2014. Functional analysis of a de
novo GRIN2A missense mutation associated with early-onset epileptic
encephalopathy. Nat. Commun. 5:3251 10.1038/ncomms4251 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]
Zarate C. A., Jr., Singh J. B., Carlson P. J., Brutsche N. E., Ameli R., Luckenbaugh
D. A., et al. (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in
treatment-resistant major depression. Arch. Gen. Psychiatry 63 856–864.
10.1001/archpsyc.63.8.856 [PubMed] [CrossRef] [Google Scholar]
Zarate C. A., Jr., Singh J. B., Quiroz J. A., De Jesus G., Denicoff K. K., Luckenbaugh
D. A., et al. (2006b). A double-blind, placebo-controlled study of memantine in the
treatment of major depression. Am. J. Psychiatry 163 153–155.
10.1176/appi.ajp.163.1.153 [PubMed] [CrossRef] [Google Scholar]
Zerangue N, Kavanaugh MP. ASCT-1 is a neutral amino acid exchanger with chloride
channel activity. J. Biol. Chem. 1996;271:27991–27994. doi:
10.1074/jbc.271.45.27991. [PubMed] [CrossRef] [Google Scholar]
Zhang L.-H., Gong N., Fei D., Xu L., Xu T.-L. (2008). Glycine uptake regulates
hippocampal network activity via glycine receptor-mediated tonic inhibition.
Neuropsychopharmacology 33 701–711. 10.1038/sj.npp.1301449 [PubMed]
[CrossRef] [Google Scholar]
94

Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P, Bading
H. (2007) Decoding NMDA receptor signaling: identification of genomic programs
specifying neuronal survival and death. Neuron 2007; 53: 549–562. [PubMed]
[Google Scholar]
Zhang W., Howe J.R., and Popescu G.K. 2008. Distinct gating modes determine the
biphasic relaxation of NMDA receptor currents. Nat. Neurosci. 11:1373–1375.
10.1038/nn.2214 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Zhao, JP., M. Constantine-Paton NR2A-/- mice lack long-term potentiation but retain
NMDA receptor and L-type Ca2+ channel-dependent long-term depression in the
juvenile superior colliculus J. Neurosci., 27 (2007), pp. 13649-13654
Zhu S., and Paoletti P. 2015. Allosteric modulators of NMDA receptors: multiple sites
and mechanisms. Curr. Opin. Pharmacol. 20:14–23. 10.1016/j.coph.2014.10.009
[PubMed] [CrossRef] [Google Scholar]
Zhu S., Stein R.A., Yoshioka C., Lee C.H., Goehring A., Mchaourab H.S., and
Gouaux E. 2016. Mechanism of NMDA Receptor Inhibition and Activation. Cell.
165:704–714. 10.1016/j.cell.2016.03.028 [PMC free article] [PubMed] [CrossRef]
[Google Scholar]

95

